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Abbreviations 
 
AGC   Adenine-guanine-cytosine kinase 
Ala (A)  Alanine 
AML   Acute myeloid leukemia 
APK   Atypical protein kinase 
Arg (R)  Arginine 
Asn (N)  Asparagine 
Asp (D)  Aspartic acid 
ATP   Adenosine tri-phosphate 
Bp   Base pair 
BRCA   BReast CAncer 
CAK   Cdk-activating kinase 
CAMK  Calcium/calmodulin-dependent kinase 
cAMP   Cyclic adenosine monophosphate 
CDC   Cell division cycle 
CDK   Cycline dipendent kinase 
cGMP   Cyclic guanosine monophosphate 
Chk    Checkpoint kinase  
CK1   Cell kinase 1 
CK2   Casein kinase 2 
CK2α336/CK2αdel CK2α deleted at residue Ser336 
CK2αpm  CK2α phosphomimetic mutant 
CK2αwt   CK2α wild type full-length 
CK2α’del  CK2α’ starting from the amino acid 3 of the wt 
CK2α’long   CK2α’ with the 14-amino acids tail of the MCS 
CK2α’wt  CK2α’ wild type  
CK2
del
   CK2 holoenzyme with the deleted form of the CK2α 
CK2
pm
   CK2 holoenzyme with the phoshomimetic mutant of CK2α 
CK2
wt
    CK2 holoenzyme with the wild type full-length CK2α  
CLK   CDC-like kinase 
CMGC  CDK, MAPK, GSK3 and CLK kinases 
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C-spine  Catalytic spine 
Cys (C)  Cysteine 
Da   Dalton 
DLS   Dynamic Light Scattering 
DMAT   2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole 
DMSO  Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
dNTP   deoxyribonucleotide triphosphate 
DRB   5,6-Dichloro-1-β- D –ribofuranosylbenzimidazole 
DTT   Dithiothreitol 
EC   Enzyme Commission 
EDTA   Ethylenediaminetetraacetic acid 
ELK   Eukaryotic Like Kinase 
EPK   Eukariotic protein kinase 
ESRF   European Synchrotron Radiation Facility 
FPLC   Fast Protein Liquid Chromatography 
Gln (Q)  Glutamine 
Gly (G)  Glycine 
GSK   Glycogen synthase kinase 
GST   Glutathione S-transferase 
His (H)  Histidine 
Ile (I)   Isoleucine 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
IRK   Insulin receptor kinase 
Kb   Kilobase 
LB   Luria-Bertani 
Leu (L)  Leucine 
LSP   Local spatial pattern 
Lys (K)  Lysine 
MAPK  Mitogen-activated protein kinase 
MAT1   Menage a trois 1 
MCS    Multiple Cloning Site) 
MDM 2  Mouse double minute 2 
Met (M)  Methionine 
Abbreviations 
3 
MM   Multiple myeloma 
OD   Optical density 
OGT   O-N-Acetylglucosamine transferase 
ON   Overnight 
PCR   Polymerase Chain Reaction 
PDB   Protein data bank 
PEG   Poly ethylenglycol 
Phe (F)  Phenylalanine 
PIM   Proviral integration of MMLV (Moloney-murine leukemia virus) 
PIN 1   Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 
Plk1   Polo-like kinase 1 
PKA/C/G  Protein kinase A/C/G 
Pro (P)   Proline 
RGC   Receptor Guanylate Cyclase 
RMSD   Root-mean-square deviation 
R-spine  Regulatory spine 
SDS-PAGE  Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis 
SEC   Size exclusion chromatography 
Ser (S)   Serine 
TBB   4,5,6,7-tetrabromo-2-azabenzimidazole 
TBI   [1,2,4]triazino[4,3-alpha]benzimidazole 
TCEP   Tris(2-carboxyethyl)phosphine 
TFIIS   Transcription factor S-II 
Thr (T)  Threonine 
TK   Tyrosine Kinase 
TKL   Tyrosine Kinase Like 
TLS   Translation/Libration/Screw 
Trp (W)  Tryptophan 
Tyr (Y)  Tyrosine 
UDP   Uridine disphosphate 
UV   Ultraviolet 
Val (V)  Valine 
wt   Wild type 
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Abstract 
 
The subject of this thesis is the protein kinase CK2 which is a family of enzymes 
that in humans consists of two catalytic subunits, termed CK2α and CK2α’, and one 
regulatory subunit, CK2β. CK2 is a highly conserved acidophilic Ser/Thr protein kinase, 
ubiquitously distributed in different cell compartments. CK2 is a member of the 
superfamily of eukaryotic protein kinases (EPKs), meaning the catalytic subunit is related 
by sequence homology and structural features to the other 478 kinases of the superfamily.  
CK2 shows some singular features like its high constitutive activity and the lack of 
an defined mode of regulation, which make CK2 unique with respect to the other kinases. 
With hundreds of substrates, this kinase is involved in several cellular events, resulting 
essential for the cell viability: CK2β gene knockout in mouse model is lethal even at 
single cell level, CK2α gene knockout are embryonic lethal at day 10.5 and CK2α' 
(expressed only in brain and testis) mouse knockout are viable with some defects in 
spermatogenesis. It participates in cell cycle progression, gene expression, cell growth, 
and differentiation and embryogenesis. Down-regulation of CK2 leads to apoptosis while 
abnormal over-activation has been found coupled to several diseases: the clinical 
relevance of CK2 is that high levels of the protein activity have been detected in a number 
of cancers, such as head and neck, renal, breast, prostate, lung, and kidney.  
A wide spectrum of cell permeable, fairly specific ATP site directed CK2 inhibitors 
are currently available which are proving useful to dissect its biological functions and 
which share the property of inducing apoptosis of cancer cells with no comparable effect 
on their “normal” counterparts. One of these, CX-4945, has recently entered clinical trials 
for the treatment of advanced solid tumors, Castelman’s disease and multiple myeloma. 
CK2 is considered constitutively active enzyme and, unlike many other protein 
kinases, it does not require phosphorylation for activation. The mechanism of regulation 
of CK2 is not firmly established yet, however it is clear that it differs from those 
commonly utilized by other protein kinases.  
Dozens of crystal structures of CK2 have been solved and highlighted the structural 
features of the main CK2 entities, the catalytic subunit CK2α, the regulatory subunit 
CK2β and the tetrameric α2β2 CK2 holoenzyme. Even if the structural knowledge of CK2 
is very extended, no high resolution 3D-structure are available for the C-terminal part of 
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CK2α, which has been deleted for the crystallization purpose. Moreover the structure of 
the CK2α’ has been solved but no structural information are present for the tetrameric 
holoenzyme with this catalytic subunit.  
To address this issue, one part of my PhD project focused on the production and the 
structural characterization of the full-length wild type CK2α and a phosphomimetic 
mutant in the tetrameric holoenzyme, in order to study the possible structural role of the 
C-terminus. Starting from the three holoenzyme structures solved we were able to 
determine some new holoenzyme structural features, in particular the new interface of 
interaction between the subunits within the tetramer and the so far unknown symmetry of 
the complex. Moreover we dealt with the development of a purification protocol of the 
CK2α’2β2 holoenzyme (and a chimeric CK2αα’β2) in quantities appropriate for structural 
approaches.  
The second part of the PhD focused on the structural characterization of a new 
potent dual inhibitor K164 which is specific for CK2 and Pim1; the crystal structure of 
the inhibitor in complex with the CK2α336 has been solved at 1.25 Å, which is the highest 
resolution ever reached for CK2. 
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Riassunto 
 
Il soggetto di questa tesi è la protein chinasi CK2, una famiglia di enzimi che negli 
uomini è composta da due subunità catalitiche, CK2α e CK2α’, e da una subunità 
regolatoria, CK2β. CK2 è una Ser/Thr protein chinasi acidofila altamente conservata nel 
mondo eucariote, presente in differenti compartimenti cellulari. CK2 è un membro della 
superfamiglia delle protein chinasi eucariotiche (EPKs), con la subunità catalitica 
correlata mediante omologia di sequenza e caratteristiche strutturali alle altre 478 chinasi 
della superfamiglia.  
CK2 mostra alcune caratteristiche singolari, come la sua elevata attività costitutiva 
e la mancanza di un importante meccanismo di regolazione, il quale rende CK2 unica 
rispetto alle altre chinasi. Con centinaia di substrati, CK2 è coinvolta in numerosi processi 
biologici, risultando essenziale per la vitalità cellulare: il knockout del gene CK2β nel 
modello murino è letale anche a livello di singola cellula, il knockout del gene CK2α è 
letale al giorno 10.5 dello sviluppo embrionale e il knockout CK2α' (espresso solo nel 
cervello e testicoli) in topo è vitale con alcuni difetti di spermatogenesi. CK2 partecipa 
alla progressione del ciclo cellulare, all'espressione genica, alla crescita cellulare e alla 
differenziazione e all’embriogenesi. Down-regulation di CK2 porta all'apoptosi cellulare 
mentre una sovra-attivazione anomala è stata trovata accoppiata a diverse malattie: la 
rilevanza clinica di CK2 risiede nel fatto che alti livelli di attività della proteina sono stati 
trovati in diversi tipi di tumori, come alla testa e al collo, ai reni, al seno, alla prostata e al 
polmone. 
Un ampio spettro di inibitori di CK2, permeabili alle cellule e specifici per il sito 
dell’ATP, sono attualmente disponibili e si stanno rivelando utili per analizzare le funzioni 
biologiche della proteina; queste piccole molecole sono in grado di indurre l'apoptosi 
delle cellule tumorali senza alcun effetto analogo sulle loro controparti "normali". Uno di 
questi inibitori, CX-4945, è recentemente entrato in studi clinici per il trattamento di 
tumori solidi avanzati, malattia di Castelman e mieloma multiplo. 
CK2 è considerato un enzima costitutivamente attivo e, a differenza di molte altre 
protein chinasi, non richiede fosforilazione per l'attivazione. Il meccanismo di 
regolazione di CK2 non è stato ancora stabilito, tuttavia è chiaro che si differenzia da 
quelli comunemente utilizzati dalle altre protein chinasi. 
Decine di strutture cristallografiche di CK2 sono state risolte e hanno evidenziato le 
caratteristiche strutturali delle principali entità di CK2: la subunità catalitica CK2α, la 
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subunità regolatoria CK2β e l’oloenzima tetramerico CK2α2β2. Anche se la conoscenza 
strutturale di CK2 è molto estesa, non è disponibile alcuna struttura 3D a elevata 
risoluzione per la parte C-terminale di CK2α, che è sempre stata deleta per scopi di 
cristallizzazione. Inoltre, malgrado la struttura di CK2α' sia stata risolta, non sono 
presenti alcune informazioni strutturali per l’oloenzima tetramerico con questa subunità 
catalitica. 
Per raggiungere questo obiettivo, una parte del mio progetto di dottorato si è 
focalizzata sulla produzione e sulla caratterizzazione strutturale di CK2α wild type 
(completa della parte C-terminale) e di un mutante fosfomimetico nell’oloenzima 
tetramerico, al fine di studiare il possibile ruolo strutturale del C-terminale. Partendo da 
tre strutture dell’oloenzima risolte abbiamo potuto determinare alcune nuove 
caratteristiche strutturali dell’oloenzima, in particolare la nuova interfaccia di interazione 
tra le subunità all'interno del tetramero e la simmetria del complesso, finora sconosciuta. 
Inoltre ci siamo occupati dello sviluppo di un protocollo di purificazione dell’oloenzima 
CK2α’2β2 (e di una forma chimerica CK2αα’β2) in quantità appropriate per approcci 
strutturali. 
La seconda parte del dottorato si è focalizzata sulla caratterizzazione strutturale del 
complesso con un nuovo potente inibitore duale (K164) il quale è specifico per CK2 e 
Pim1; la struttura cristallina di CK2α336 in complesso con l’inibitore è stata risolta a 1.25 
Å, che è la più alta risoluzione mai raggiunta per CK2. 
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1. Introduction 
1.1. Protein kinase introduction and classification 
The importance of protein phosphorylation as a regulatory mechanism was 
discovered by Krebs and Fisher nearly 50 years ago: they found that glycogen 
phosphorylase was activated by a reversible addiction of a phosphate group by a protein 
kinase (phophorylase kinase) (Krebs, 1998). The second protein kinase to be discovered 
was the cAMP-dependent protein kinase (PKA) in the 1968 (Walsh et al., 1968). With the 
advent of DNA cloning and sequencing in the mid-1970s, it rapidly became clear that a 
large family of eukaryotic protein kinases exists. After the completion of the human 
genome sequence it was possible to identify almost all the human protein kinases: the 
human kinome is composed by 518 kinases, 478 human EPKs and 40 APK, and they are 
encoded by the 1.7% of all human genes (Manning et al., 2002). Emphasizing the 
importance of phosphorylation is the estimate that one third of cellular proteins are 
phosphorylated (Ahn and Resing, 2001) and often at different sites (Cohen, 2000). The 
major part of the protein kinases belong to the EPKs superfamily and can be classified 
into 9 broad groups, divided in families and subfamilies (Table 1.1). The classification is 
based primarily on kinase domain similarity, deduced from pairwise and multiple 
sequence alignments and phylogeny; knowledge on sequence similarity, domain 
structures outside the catalytic domains and known biological functions were used to 
refine the classification (Manning et al., 2002 b). 
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Table 1.1 Kinase distribution by broad groups in human 
Group Families Subfamilies Human kinase 
AGC 14 21 63 
CAMK 17 33 74 
CK1 3 5 12 
CMGC 8 24 61 
STE 3 13 47 
TK 30 30 90 
TKL 7 13 43 
RGC 1 1 5 
Other 37 39 83 
aPKs 14 22 40 
Total 134 201 518 
 
The AGC group protein kinases (named after the PKA, PKC, PKG) tend to be basic 
amino acid-directed enzymes, phosphorylating substrates at Ser/Thr lying very near Arg 
or Lys; this group contains many cytoplasmic serine/threonine kinases that are regulated 
by secondary messengers such as cyclic AMP (PKA) or lipids (PKC). 
The CAMK group protein kinase also tend to be basic amino acid-directed; many 
but not all of the kinases members of this group are known to be activated by 
Ca
2+
/calmodulin binding to a small domain located near the catalytic domain 
(Calmodulin/Calcium regulated kinases). 
CK1 group (Cell Kinase 1) is a small group of kinases very similar to each other in 
sequence but very different from the structural point of view from the other ePKs, with 
several conserved motifs which are modified in the CK1 group. 
CMGC group (named after another set of families CDK, MAPK, GSK3 and CLK) 
is composed by Ser/Thr protein kinases which mainly phosphorylate residues lying near a 
Pro-rich environments and involved in cell-cycle control, stress response, splicing and 
metabolic control. Part of this group are for example the CDKs (Cycline dipendent 
kinases) and CK2 family which fail to conform the proline-directed specificity showing 
instead a strong preference for Ser residues located NH2-terminal to a cluster of acidic 
residues. 
TK group (Tyrosine Kinase) includes a large number of enzymes with quite closely 
related kinase domains that specifically phosphorylate on Tyr residues. This group is very 
young from the evolutionary point of view and it is absent from plants and unicellular 
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organism. Due to the fact that their function is related to the transmission of extracellular 
signal into the cell, half of TKs are cell receptor and many of the others are close to the 
surface of the cell. 
TKL group (Tyrosine Kinase Like) is composed by kinases relatively weakly 
related to each other, and all are also similar to members of the TK (Tyrosine Kinase) 
group, though they generally lack the TK-specific motifs of the TK group and whose 
activities are generally on serine/threonine substrates. 
RGC group (Receptor Guanylate Cyclases) are single-pass transmembrane 
receptors with an extracellular active guanylate cyclase domain and a cytoplasmatic 
catalytically inactive kinase domain. The guanylate cyclase domain makes the second 
messenger cGMP, and the intracellular kinase domain appears to have a regulatory 
function (Hanks and Hunter, 1995). 
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1.2. Structural features of kinases 
We discuss the classification of the protein kinases in 9 broad groups and how they 
differ from each other in this nomenclature; because now we have a significant 
“structural” kinome available, composed of over 150 protein kinases (Taylor and Kornev, 
2011), in this paragraph I will analyze the general unique structure features of the EPKs 
superfamily. All the kinases of the EPKs superfamily are characterized by a conserved 
kinase core: this core is composed by a bi-lobal protein of approximately 250 amino 
acids. The catalytic cleft is positioned in the middle of the protein, where the two lobes 
convert to form a deep cleft where the adenine ring of the ATP is bound and the δ-
phosphate points at the outer edge of the cleft. Catalysis is mediated by opening and 
closing of the active site cleft allowing for transfer of the phosphate and then release of 
the nucleotide (Taylor et al., 2012). 
The N-terminal lobe (N-lobe) is composed of 5 anti-parallel beta sheet and one 
single conserved αC-helix (between β strand 3 and 4); β strand 1 and 2 are linked by a 
gly-rich loop which stays on top of the adenine ring and blocks the δ-phosphate of the 
ATP on a correct conformation for the catalysis. β strand 3 interacts with the αC-helix by 
a coupling between a conserved Lys residue (Lys72 in PKA and Lys68 in CK2) and a 
conserved Glu residue in the helix (Glu91 in PKA and Glu81 in CK2) when the kinase is 
in an active state. 
In contrast the C-terminal lobe (C-lobe), covalently linked to the N-lobe by the so-
called hinge region, is mainly composed of alpha helix with four-stranded beta sheet 
leaning on the top of the lobe. And these beta sheets contain the other two conserved 
residues fundamental for the catalysis: the catalytic base of the catalytic loop (Asp164 in 
PKA and Asp156 in CK2) and the conserved motif Asp-Phe/Trp-Gly (DFG in PKA and 
DWG in CK2) where a conserved Asp residue (Asp184 in PKA and Asp175 in CK2) 
binds to the catalytic magnesium ion (Figures 1.1 and 1.2). 
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Figure 1.1 Conserved core of the eukaryotic protein kinases. The bottom panels (c–e) highlight 
functional motifs in the N-lobe (a) and the C-lobe (b) using PKA as a prototype for the EPK 
family. Helices are shown in red; β-strands in teal. (a) The N-lobe contains five β-strands and a 
large αC-helix. (b) The C-lobe is mostly helical with a large activation segment. A four-stranded 
β-sheet rests on the helical core and forms one surface of the active site cleft. ATP is bound in the 
cleft between the two lobes. (c) The phosphates of ATP are positioned by a conserved glycine-rich 
loop between the β1- and β2-strands. (d) Conserved residues Lys72 from the β3-strand, Glu91 
from the αC-helix, and Asp164 from the DFG motif in the activation segment where Mg2+ ions are 
show as purple balls. (e) The catalytic loop also contains a set of catalytically important residues: 
Asp166, Lys168, Asn171 (Taylor et al., 2012). 
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Figure 1.2 Structure-based sequence alignment (by 3D-Coffee) of human CK2, PDB 3NSZ, and 
human PKA, PDB 3AGM (enhanced by ESPript Web-server). Elements of the CK2 secondary 
structure are indicated (α=α-helix; β=β-strand; η=310-helix; T=Turn). Conserved and 
homologues residues are indicated in white on a black background and in contoured boxes, 
respectively. Numbering refers to the human CK2 sequence. The secondary structure of the C-
terminal tail of CK2 (from residue 333) is unknown (NIefind et al., 2012). 
 
In the last two decades hundreds of EPKs representing various functional and 
binding states have been published and this allow to determine additional conserved 
structural elements. A rigorous comparison between many protein kinase structures 
revealed that the conserved catalytic core is built around a stable yet dynamic 
hydrophobic core, made up of three essential elements: a single hydrophobic helix that 
spans the large lobe (αF- helix) and two hydrophobic spines which connect the N-lobe 
and the C-lobe and that are each made up of non-contiguous residues from both lobes 
(Taylor et al., 2012). 
The spine concept arises from a new approach of sequence comparison based on the 
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novel “local spatial pattern” (LSP) alignment procedure (Kornev et al., 2006). The first 
application led to the detection, by the analysis of only solvent accessible residues, of an 
hydrophobic spine composed of two residues of the N-lobe and two residues of the C-
lobe (in PKA: Leu106, Leu95, Phe185 and Tyr164). This spine connects the two lobes in 
a non-covalent manner and, because this spine is broken in the inactive kinases, was later 
renamed “regulatory spine” (or “R-spine”). 
When the LSP approach was used to compare all residues of all the published 
kinases, another hydrophobic spine, that runs parallel to the R-spine, became visible 
(Kornev et al., 2008). Unlike the R-spine this spine is always opened and it is completed 
only by the adenine ring of the ATP; this spine was therefore called “catalytic spine” (or 
“C-spine”). Both spines are anchored to the αF- helix (Figure 1.3). 
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Figure 1.3 Hydrophobic spines define the internal architecture of the EPKs. (a) Two hydrophobic 
spines span the two lobes of the kinase core and provide a firm but flexible connection between 
the N- and C-lobes. (b) The regulatory spine (R-spine) contains four residues from different kinase 
subdomains and is anchored to the αF-helix by conserved Asp220. The catalytic spine (C-spine) is 
completed by ATP. (c,d) In the inactive state, the R-spine is typically disassembled. Disassembly 
of the R-spine can be achieved in different ways: by movement of the αC-helix like in cyclin-
dependent kinase 2 (CDK2) (c) or by movement of the activation segment like in insulin receptor 
kinase (IRK) (d) (Taylor et al., 2012). 
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1.3. CK2  
1.3.1 Introduction 
The correct regulation of protein phosphorylation is fundamental for the correct 
function of the cellular signaling pathways, and loss of regulation in these pathways 
underlies many human diseases, including cancer (Hanahan and Weinberg, 2000). CK2 is 
a small family of protein serine/threonine kinases that is overexpressed in multiple forms 
of cancer and has oncogenic proprieties in mice and cultured fibroblasts (Litchfield, 
2003). 
Originally discovered in 1954 (Burnett and Kennedy, 1954), CK2 is a family of 
enzymes that in humans consists of two catalytic subunits, termed CK2α and CK2α’, and 
one regulatory subunit, CK2β (St-Denis and Litchfield, 2009). 
CK2 is fundamental for cell viability: regulatory CK2β gene knockout in mouse 
model is lethal even at single cell level (Buchou et al., 2003), CK2α gene knockout are 
embryonic lethal at day 10.5 (Lou et al., 2008) and CK2α' (expressed only in brain and 
testis) mouse knockout are viable with some defects in spermatogenesis (Xu et al., 1999). 
CK2 is a member of the superfamily of eukaryotic protein kinases (EPKs), meaning 
the catalytic subunit is related by sequence homology and structural features to the other 
478 kinases of the family in a way as described before. However CK2 shows some 
incredible features like its high constitutive activity and the lack of an acute mode of 
regulation, which make CK2 unique with respect the other kinases (Pinna, 2002). 
At the beginning acidic phosphoproteins, like casein, were used as artificial 
substrates for CK2 but only in the 1980ies was found that negatively charged residues 
near the phosphorylatable serine or threonine was fundamental for CK2 substrate 
recognition (Pinna et al., 1984). The first physiological substrates of CK2 was discovered 
more than 20 years after its identification: CK2 was discovered to be one of the enzymes 
responsible for the phosphorylation of the “glycogen synthase 5” (GSK5) and “Troponin-
T kinase” (Pinna, 1994). 
The minimal consensus sequence for CK2 phosphorylation was published in 1988 
to be S/T-X-X-D/E (Marchiori et al., 1988) and now the number of proteins 
phosphorylated by CK2 amount to more than 300 substrates (Meggio and Pinna, 2003). 
This number seems to underestimate the whole “CK2 phosphoproteome” if we consider 
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that consensus sequence analysis performed on a database of 10.899 naturally 
phosphorylated sites reveal that 2.275 of these (>20%) display the unique acid pattern of 
CK2 (Salvi et al., 2009). 
Due to this broad substrate spectrum CK2 belongs to EC class 2.7.11.1 (Scheer et 
al., 2011), i.e. to the non-specific serine/threonine protein phosphotransferases. 
In the introduction to the kinase superfamily, we saw how the mechanism of 
binding of an ATP molecule is conserved within the kinases and this is because ATP is the 
typical cosubstrate of an EPK; interestingly CK2 is able to use, alternatively to the ATP, a 
GTP molecule as cosubstrate (Rodnight and Lavin, 1964). This double specificity entails 
structural features in the binding site peculiar to CK2. 
 
1.3.2 CK2 cell cycle 
CK2 has been reported to be fundamental for cell viability and it is involved in 
every stage of cell cycle progression (Table 1.2) phosphorylating different proteins crucial 
to the successful production of daughter cells (Litchfield, 2003). 
Table 1.2 Cell cycle’s phases description. 
State Abbreviation Description 
Quiescent/ 
senescent 
G0 In this phase the cell has left the cell 
cycle, and it's in a quiescent state. 
 
 
 
 
 
Interfase 
G1 Also called the “growth phase”, cell 
starts the synthesis of new proteins 
required for the new cell and for the 
DNA replication. The G1 checkpoint 
controls that everything is correct for 
the DNA duplication (under the 
control of p53 and consequentially 
p21)       
S In this phase the DNA is replicated in 
two copies. 
G2 After the DNA synthesis, the cell 
continues to grow and the G2 
checkpoint ensures the cell is ready for 
the mitosis (under favourable 
conditions phosphatase cdc25 
activates the CyclineB/CDK1 
complex) 
Cell 
division 
M In this phase the cell starts the division 
in two daughter cells. There's another 
checkpoint in the middle of the mitosis 
for the correct cell division. 
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In mammalian cells, the inhibition of CK2 with specific inhibitor or CK2 antibodies 
can all stop the cell cycle progression, meaning that mammalian cells require CK2 for 
G0/G1, G1/S, and G2/M transitions (Lorenz et al., 1993; Lorenz et al., 1994; Pepperkok et 
al., 1994). 
Cdks are the main characters in the cell cycle progression, and they are controlled 
by an extremely precise activation-deactivation mechanism: Cdk4/Cyclin D at the G1/S 
transition, and Cdk1/Cyclin B at the G2/M transition (Nasmyth, 1996). The Cdk-
activating kinase (CAK) is an enzyme complex composed of Cdk7, Cyc H and MAT 1 
and it activates the mentioned kinases in the appropriate times: this activator is regulated 
by the CK2 phosphorylation itself and the activity is modulated by this phosphorylation. 
Another well studied CK2 substrate involved in cell cycle regulation is the tumor 
suppressor protein p53. P53 is a transcription factor which can induce the cell cycle arrest 
and eventually the programmed cell death (apoptosis) (Sherr and McCormick, 2002). The 
phosphorylation of p53 by CK2 comes in response to a UV radiation DNA damage, and 
increase the p53 activity enhancing its DNA binding and transcriptional activation 
(Kapoor and Lozano, 1998). In normal cells, p53 is constantly produced and degraded 
and the degradation is induced by MDM-2 protein; MDM-2 protein is also a CK2 
substrate and its phosphorylation leads to a decreased capability to induce p53 
degradation favouring the cell cycle arrest (Hjerrild et al., 2001). Moreover the inhibition 
of CK2 with TBB (4,5,6,7-tetrabromo-2-azabenzimidazole) leads to cell cycle arrest and 
apoptosis induced by p53, confirming CK2 involvement in this mechanism. 
CK2 is phosphorylated itself in a cell cycle-dependent manner by the Cdk1 at Ser 
209 of the CK2β (which the function is unknown) (Litchfield et al., 1991), and at four 
residues located at the C-terminal domain of CK2α (Thr 344 and 360 and Ser 362 and 
370) (Bosc et al., 1995). The presence of this phosphorylation sites indicates that CK2 has 
a specific role in mitosis and, even if the phosphorylation doesn't affect the CK2 activity, 
could be a binding site for different interacting proteins targeting CK2 towards favourable 
substrates or away from unfavourable substrates during the mitotic progression (St-Denis 
and Litchfield, 2009). There aren't any structural data about this C-terminal tail of CK2α, 
because all the 39 structures deposited in the PDB database lack this portion of protein, 
but it has been reported that the disruption of these phosphorylation sites by mutating in 
alanine residues, prompt to mitotic catastrophe: this means that CK2 has also a crucial 
role in mitosis progression (St-Denis et al., 2009). For example it has been demonstrated 
that Pin1, a peptidyl-prolyl isomerase which catalyzes the cis-trans isomerization of 
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proline residues adjacent to phosphorylated serine or threonine and which is believed to 
have a central role in mitosis, can bind CK2α via its phosphorylated C-terminal tail 
(Messenger et al., 2002). This interaction could actually catalyze isomerization of the 
prolines, but is known that it modulates CK2 activity. 
As in G1/S transition, CK2 is involved in the p53-mediated DNA damage 
checkpoint in G2 and many different proteins involved are reported to be CK2 substrates 
like checkpoint kinases Chk1 and Chk2, Topoisomerase II, BRCA and Plk1 (St-Denis and 
Litchfield, 2009); by the way, the role of CK2 in the DNA damage response in G2/M 
remains unknown. 
On the other hand, CK2 has been reported to be an important pro survival enzyme 
because the overexpression of CK2 is protective for drug-induced apoptosis and cell lines 
which show drug-resistant phenotype often overexpress CK2 (Di Maira et al., 2008). As a 
consequence the chemical inhibition of CK2 is able to induce apoptosis in cancer cells 
and makes CK2 a putative target for cancer treatment. In particular CK2 is involved in 
protein protection from caspase cleavage: the sequence consensus of CK2 recognition 
(S/T-X-X-Acidic) for phosphorylation is very similar to the consensus recognized by 
protein caspases which act at the level of an aspartic residue. So phosphorylating proteins 
at serine or threonine close to an aspartic acid can protect the proteins from caspase 
recognition and the apoptosis is avoided (Tozser et al., 2003). In addition CK2 can also 
directly regulate the caspase activity for example by means of phosphorylating caspase 9 
and protecting it from caspase 8 cleavage, or phosphorylating caspase 2 and preventing its 
dimerization/activation (McDonnell et al., 2008; Shin et al., 2005). Taken together, all of 
these implications of CK2 in cell cycle regulation and apoptosis make clear that a down 
regulation of CK2 may cause drastic and important consequences in the cell ending with 
high probability in an oncogenic phenotype. More deeply CK2 is not itself an oncogene, 
which is a gene that has the potential to cause cancer and usually it’s mutated and 
overexpressed in certain types of cancer cells, but has a role on ensuring survival of a 
wide variety of cancer where its high activity is not due to genetic modification but to the 
alteration of the global chemical environment inside the cell; and in this direction, it has 
been proposed that different kind of tumors became somehow “addicted” to CK2 
(Ruzzene and Pinna, 2010). While CK2 is expressed in all cells, normal or transformed, 
its level and possibly its substrates significantly differ and this suggests that tumor cells 
rely more deeply on CK2 activity for their survival pathway than normal cells do. The 
number of tumor and cancer cells that crucially depend on CK2 levels for their survival is 
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continuously growing (Table 1.3): 
 
Table 1.3 Cell lines which show a high level of activity of CK2. 
Neoplasia Cell type 
T-cell leukemia Jurkat, CEM , HPB-ALL, TAIL-7, primary cells 
Burkitt lymphoma Raji 
MM OPM2, U266, RPMI 8226, 
primary cells 
BCR/ABL-positive 
lymphoblastic leukemia 
PLC1, B1, B2 
AML NB4, HL60, primary cells 
NPM/Alk-positive ALCL Karpas299, SR786, SUDHL 1 
Murine leukemia P388 
Osteosarcoma U2OS 
Ovarian carcinoma 2008 
Prostate carcinoma PC-3, LNCaP, DU-145, ALVA-41 
Colon carcinoma HCT8, HCT116, HT29 ,DLD-1, SW-480 
Hepatocellular carcinoma HepG2, Hep3B 
Endometrial cancer IK, RL95, primary cells 
Rabdomiosarcoma JR1, Rh30, RD 
Pancreatic cancer MiaPaCa2, DanG 
Cervical cancer HeLa 
Breast cancer MCF-7, NF639, ZR-75, SKBr-3, Hs578T, MDA231 
Squamous cell carcinoma SCC-15  
Lung carcinoma A549, H1299 
 Based on Ruzzene and Pinna 2010. 
 
What makes CK2 atypical from the other kinases is that it is not implicated in 
“hierarchical” signaling cascades but it rather plays a “lateral” role acting in different 
“longitudinal” pathways: due to this involvement in different pathways it is difficult to 
determine which are essential and which are more “complementary”. So CK2 must be 
considered as a “master kinase” which has the ability to integrate and consolidate 
different biological mechanism.  
The scenery is even more complicated due to the lack of a clear mechanism of 
regulation for CK2. CK2 has been considered for decades a “constitutive active” kinase 
and this adjective has found structural meanings in all of the structures published in the 
database. In the next chapter I will discuss all of the peculiar structural features of CK2 
and how the biological activity of CK2 finds its answer in the crystal structure.  
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1.3.3 Structural Biology of CK2 
CK2 has in the cell a tetrameric architecture composed of a CK2β2 dimer and two catalytic 
subunits CK2α or α’ which can also combine giving a chimeric holoenzyme (CK2α2β2 CK2α’2β2 
or CK2αα’β2). The structural analysis of CK2 started in the 1990ies and now in the database are 
present more than 60 structures of different CK2 subunits. The more studied are the CK2α and the 
CK2β and only two structures are present for the CK2α’ and for the CK2 holoenzyme. 
 
1.3.3.1 CK2 catalytic subunit 
CK2 catalytic subunit has the canonical bilobal shape of an EPK, with the N-lobe composed of β-
sheet and only one conserved α helix, and the C-lobe predominantly composed by α helix. We can 
actually divide the N-lobe in two different regions composed of the conserved αC-helix and the 
layer of five stranded antiparaller β-sheet. In this region is present a second binding site for CK2α, 
composed of an hydrophobic cleft within the β-sheet layer, and it was found to be the interface 
region for the regulatory β subunit for the first time in a structure of catalytic maize enzyme in 
complex with the C-terminal tail of the CKβ subunit (Battistutta et al., 2000) (Figure 1.4).  
 
 
Figure 1.4 Close-up view of the secondary (allosteric) binding site occupied by the β peptide 
[181-203], in the N-terminal lobe of the α-subunit (shown as surface). This is the site of major 
interaction between the α and the β subunits in the tetrametric α2β2 holoenzyme (Niefind et al., 
2012). 
 
In order to have the binding, a small loop between the β-sheet 4 and 5 (loop β4β5) 
has to assume a stretched conformation instead of a close one. The binding of the β 
subunit is incompatible with the close one and it was proposed that the opening of this 
loop could have a functional importance as a driving force for the interaction (Raaf et al., 
2008). This hypothesis was confuted by a recent work (Papinutto et al., 2012) were we 
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showed that both of the conformations can occur without any apparent correlation with 
the occupation of the secondary binding site. 
Under the β-sheet layer there’s the nucleotide binding site: the Lys68 and the Glu81 
are conserved residues among all the EPKs and they are part of the β3 strand and of the 
αC-helix respectively and they’re involved in the interaction with the α and β phosphate 
group of the ATP (Figure 1.5).  
 
 
Figure 1.5 Schematic drawing of the coordination of ATP within the active site and of the 
catalytic key residues. Important hydrogen bonds and coordinative bonds with the two magnesium 
ions are indicated by dashed lines. Water molecules completing the Mg
2+
 coordination shells are 
left out. The sequence numbers refer to CK2α. The phosphoacceptor region shows the minimal 
recognition sequence of CK2α substrates (Niefind et al., 2012). 
 
The aromatic ring of the ATP (or GTP) is surrounded and stabilized by the residues 
Val66 (part also of the C-spine) from strand β3, Val45 from strand β1, Val53 from strand 
β2 and Phe113 from strand β5 which create a hydrophobic compartment. This 
hydrophobic well is fundamental also for the design of CK2 inhibitors with high 
specificity and for their binding. The C-lobe of the catalytic subunit is crossed by the 
large and conserved αF-helix which is the basis for the two hydrophobic spines that link 
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the two lobes. 
Another important region in the C-lobe is the “activation segment”. This element 
distinguishes EPKs from ELKs (Eukaryotic Like Kinase, which are prokaryotic kinase), 
and arises during the evolution answering to the necessity of a strictly regulation 
mechanism. Actually the activation segment plays a fundamental role in this context: it is 
formed by the magnesium binding loop (DFG/DWG motif), the “activation loop” and the 
P+1 loop. In many EPKs the activation loop can assume two different conformations, one 
fully active and the other inactive, by large rearrangement of the structure, usually due to 
a phosphorylation of one or more residues of the loop. In CK2 no phosphorylation site is 
present on the loop and no conformational change was observed within the more than 60 
structures of CK2α published to date (Niefind et al., 2009). A more detailed structural 
analysis of all of the structures of CK2α confirmed that the activation loop is always in a 
conformation that is very similar to the fully active state of the nearest kinases in the 
EPKs (CDKs and MAP kinases). This is due to intense contact between the N-terminal 
domain and the activation loop giving a final structure where the αC-helix, the activation 
segment and the N-terminal domain is free from plasticity. One of the structural reasons 
for the impossibility of the activation loop to undergo a huge conformational change is an 
hydrogen bond across the β8–β9 joining loop between Trp176-NE1 and Leu173-O. In this 
way, the active state of the activation segment is stabilized by an internal constraint in 
addition to the contact with the N-terminal region (Niefind et al., 1998). Moreover the 
Trp176 goes more deeply in the hydrophobic core of the protein, and it makes 37 non-
covalent contacts with the atoms of the environment, stabilizing the active conformation. 
Interestingly CK2α and CK2α' are the only kinases of the EPKs with a Trp instead of a 
Phe in the DFG/DWG triplet; a recent analysis on the active state of the EPKs found that 
this phenylalanine (DFG) is part of the R-spine, and that the spine is completed and fully 
active only with the phenylalanine in the DFG-in conformation. In the CK2α (or α') this 
conformation is the only possible, due to structural contacts listed before, and this 
strengthens the constitutively active character of the protein (Figure 1.6). 
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Figure 1.6 The central side chain of the DFG-motif – a member of the regulatory spine and its 
atomic contacts to neighbouring residues. The atomic contacts are drawn by dashed lines with a 
cutoff of 4 Å. (A) CK2α (from maize) with the unique mutation of the DFG-motif to DW176G. More 
than 30 atomic contacts are indicated, among them a 3-Å-hydrogen bond from the Trp176 side 
chain to the peptide carbonyl oxygen of Leu173. (B) PKA with a canonical DFG-motif in the 
“DFG-in” conformation. A comparison of the two panels reveals the intensive embedding of the 
Trp176 side chain into its hydrophobic environment (Niefind et al., 2012). 
 
Interesting and important region of the catalytic subunit is the so called hinge/αD 
helix which is responsible for the double dual-cosubstrate specificity. The hinge region 
connects the two lobes of the protein and supplies the hydrogen bonding counterparts for 
the binding of the adenine and guanine base of ATP or GTP. The hinge region is able to 
adopt two different conformations, an open and a close one, with the open conformation 
creating lot of space in the region of nucleotide binding site, giving the possibility of a 
dual-cosubstrate specificity due to an “hydrogen bond frame shift” of the two ligands 
(Figure 1.7). 
This open conformation of the hinge region, reported for all the structures of maize 
CK2α, CK2α' and many structures of human CK2α, is unique in all the EPKs structures 
published to date. In this conformation the conserved R-spine is not correctly assembled 
because the Phe121 (equivalent to the C-spine member Met128 of PKA) is not stabilized 
by hydrophobic interaction with the other components of the R-spine and prefers an open 
conformation. But the hinge region of CK2α shows an untypical structural plasticity and 
it has been reported that also a close conformation is possible (Raaf et al., 2008b) and in 
this close conformation the R-spine is completely and correctly assembled in a EPK-
canonical way (Battistutta and Lolli, 2011). So which is the “correct conformation” of the 
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hinge region? A recent analysis of 7 new structures of CK2α, proposed that there's not a 
clear correlation between all these flexible regions of the protein and that probably in 
solution there is an equilibrium between the two main conformations and a variety of 
subpopulation concerning the side chains (Papinutto et al., 2012) (Figure 1.7). 
 
 
Figure 1.7 The hinge/helix αD region: (A) Maize CK2α in complex with either an ATP- or a 
GTP-analogue. Hydrogen bonds between the purine bases and the hinge region important for 
binding and recognition are indicated by dashed lines. Bulky side chains that determine the 
“purine-base binding plane” are drawn embedded in a molecular surface. For comparison the 
equivalent side chains of aminoglycoside phosphotransferase 2’’-IV, an enzyme with a similar 
dual-cosubstrate specificity like CK2 were drawn with small black bonds. (B) The hinge/helix αD 
region of human CK2α with an open (black) and with a closed conformation (grey). The catalytic 
spine residues of human CK2α covered by a molecular surface. Phe121 is equivalent to the 
CAPK-C-spine member Met128 and can adopt the EPK-canonical position only in the context of 
the closed conformation of the hinge/helix αD region (Niefind et al., 2012). 
 
Another unique feature of human CK2 paralogs (CK2α and CKα') is the C-terminal 
extension: this C-terminal extension is different in sequence and length and it was 
hypothesized to be the source of functional differentiation and regulation between CK2α 
and CK2α'. To strengthen this hypothesis it has been reported that the C-terminal tail of 
CK2α has four phosphorylation sites, phosphorylated in a cell cycle manner by Cdk1 
(Bosc et al., 1995), and has also a glycosylation site (Tarrant et al., 2012) in contrast to 
human CK2α'. None structural information is available for the CK2α C-terminal tail 
because it undergoes to spontaneously degradation, or it has been truncated by 
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mutagenesis from crystallization trials. The only structural information for the C-terminal 
tail of CK2α is given by the crystal structure of the complex between the O-linked β-N-
acetylglucosamine and the G
341
GSTPVSSANM352 portion of the C-terminal tail of 
human CK2α. The OGT is an enzyme which catalyze the transfer of an N-
acetylglucosamine group from uridine disphosphate (UDP) N-acetylglucosamine to serine 
side chains of protein and peptide substrates, among them to Ser347 from the C-terminal 
segment of human CK2α (Tarrant et al., 2012). In the complex the peptide assumes a bent 
conformation and is well ordered in the crystal structure (Figure 1.8). 
 
 
Figure 1.8 Ternary complex structure of human O-acetylglucosamine transferase (OGT) with 
uridine disphosphate (UDP) and a peptide substrate derived from the (otherwise disordered) C-
terminal tail of human CK2α. UDP is the coproduct of the OGT-reaction after transfer of the 
acetylglucosamine moiety to a serine side chain of a substrate (Niefind et al., 2012). 
 
1.3.3.2 CK2 regulatory subunit 
The regulatory subunit is an obligate dimer and only in this form has a structural 
stability and a functional competence (Canton et al., 2001). The monomer of CK2β can 
be divided in two structural sub-domains: domain I (N-terminal domain) and domain II 
(C-terminal domain). The domain I is composed mainly by α-helix (αA, αB, αC, αD and 
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αE) where αD (40 Å long) and αE form a “L” structure, as stem and base respectively. 
Another important region of the domain I is the “acidic groove” composed by elements 
from αC (Asp51), αD (Asp70, Glu73, Glu77) and the loop connecting the two helix 
named “acidic loop” (Asp55, Glu57, Asp59, Glu60, Glu61, Glu63, Asp64) (Chantalat et 
al., 1999). This acidic cluster has been reported to be able to bind polyamines like 
spermine (Leroy et al., 1995), polycationic molecules that are able to stimulate the CK2 
activity in vitro. A similar up-regulating effect has been detected with mutational studies 
on this region, where negative charge was reduced by substituting charged residues with 
alanine resides. For years it has been proposed that the acidic loop could have a down-
regulatory effect on the CK2 holoenzyme activity; but this hypothesis was always 
weakened by the distance reported in the CK2 crystal structure between the catalytic cleft 
and the acidic loop. (Niefind et al., 2001) Only recently a new crystal structure of the 
holoenzyme seems to have clarified the mechanism of how CK2 can undergoes to an 
autoinhibitory polymerization mediated by the acidic loop (Lolli et al., 2012). The 
domain II is composed of three-stranded beta sheet and one single α-helix (αF). In this 
domain 4 conserved cysteines (Cys109, Cys114, Cys137 and Cys140) are involved in a 
Zn
2+
 binding motif, which is very similar to the zinc-binding site of the transcriptional 
elongation factor TFIIS. To avoid aggregation problems with the full length β-subunit, the 
last 35 amino acids were deleted for obtaining the crystal structure of the dimer; these 
residues are implicated in the CK2α binding as proved by mutational studies (Boldyreff et 
al., 1993) and are able to bind also to the maize catalytic subunit (Battistutta et al., 2000) 
(Figure 1.4). These 35 amino acids don't make any contact with the body of the monomer 
and they cross the entire dimer in contact with the other monomer up to Tyr188 where it 
makes a deviation forming two-stranded antiparallel β-sheet (β4 and β5) fundamental for 
the CK2α binding (Figure 1.9). In the last structure published of the holoenzyme (PDB 
code 4DGL) the entire C-terminal tail, until residue Arg215, has been defined for the first 
time, and it is in contact in the crystal with some residues of the catalytic cleft coming 
from a neighboring tetramer (Lolli et al., 2012). 
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Figure 1.9 CK2β tail (black) penetrating the dimer interface and being attached to the CK2β 
body of the neighbouring subunit. The CK2β body dimer is covered with a molecular surface 
(Niefind et al., 2012). 
 
1.3.3.3 CK2 holoenzyme 
In vivo the fully functional form of CK2 is considered the α2β2 holoenzyme, a 
heterocomplex of 140 kDa composed of two catalytic α-subunits and two regulatory β-
subunits. Only two structures for the holoenzyme are available dated 2001 (PDB code 
1JWH) (Niefind et al., 2001) and 2012 (PDB code 4DGL) (Lolli et al., 2012), and they 
represent the only structural knowledge about the α/β interaction to date: 
- a central β2 dimer recruiting two catalytic α-subunits on opposite sites; 
- the global architecture has a butterfly shaped enzyme; 
- the two α-subunits attached to the β2 dimer do not touch each other; 
- the C-terminal tail of the β-subunit is the main element involved in the α/β 
interface; 
- the α interface is located in the outer part of the N-lobe β-sheet. 
The formation of the holoenzyme causes only minor conformational changes 
between CK2β-bound and unbound CK2α, leaving unaltered the structural determinants 
for an effective catalysis, already present in the isolated α-subunit (Lolli et al., 2012), in 
accordance to the constitutive active enzyme. So the structure of the holoenzyme doesn't 
explain how the CK2β is able to modulate the activity of the CK2α and if there is a 
regulation mechanism hidden behind this interaction. 
 
1.3. CK2 
30 
 
Figure 1.10 Structure of a heterotetrameric human CK2 holoenzyme complex (Niefind et al., 
2001; PDB 1JWH) and disclosing the fact that the CK2α/CK2β interface is formed by three 
protomers, namely one CK2α subunit and both CK2β chains (Niefind et al., 2012). 
 
From the structures of the holoenzyme it is clear that both of the CK2β monomers 
cooperate to form the α/β interface giving a final heterotrimeric contact (Niefind et al., 
2001): as said before, the main interaction element is the C-terminal tail of one CK2β 
monomer which gives a total interaction area of 490 Å
2
 (1JWH) (603 Å
2
 for 4DGL). But 
this is complemented by about 340 Å
2
 (415 Å
2
 for 4DGL) arisen from the contact with 
the other CK2β monomer. This last contact involves elements from the body of the 
regulatory subunit, mainly from αF-helix and in minor parts from αD-helix and is 
fundamental to increase the total interaction area to a main value of 830 Å
2
 (1018 Å
2
 
4DGL). This value draws the attention of the scientists to the total interaction area 
required for a stable or transient complex; in particular it was hypothesized that this 
relatively small interaction area was sufficient only for a non-permanent protein/protein 
complex (Niefind et al., 2001) which is in contrast to the reported strong denaturation 
condition to dissociate the complex. The main residues involved in the interaction are the 
Tyr188 and Phe190 as proved by mutational experiments (Laudet et al., 2007) and by the 
structure 4DGL which shows how the Phe190 fills the hydrophobic cavity of the α-
catalytic subunit (Lolli et al., 2012). As reported before, CK2 has been considered for 
years a “constitutive active” enzyme due to the lack of clear mechanism of regulation for 
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the kinase. One of the first methods of regulation proposed for CK2 comes from the 
tendency of CK2 to form regular aggregates under certain conditions (Glover, 1986). In 
1986 Glover found that aggregation of Drosophila CK2 at low ionic strength results from 
a polymerization of the enzyme to form linear filaments. The forces that stabilize the 
polymer were in contrast with the forces that stabilize the tetramer (stable up to 1M 
NaCl). The results were confirmed in 1995 by Valero and co-workers (Valero et al., 1995) 
and they were able to distinguish three different form of CK2 composed by the single 
protomer, a ring-like structure and a filamentous form. Another interesting feature of CK2 
which could be involved in the regulation of the enzyme is that CK2 is found extensively 
autophosphorylated in vivo, when obtained from cells (Litchfield et al., 1991). The 
autophosphorylation sites are βSer2 and βSer3 and mutation in alanines of the acidic 
residues of the acidic loop prompt to a inhibition of the autophosphorylation and to an 
hyperactivation of the enzyme (Pagano et al., 2005). All of these singular features of CK2 
are elegantly described by a structural point of view, in the last structure of the 
holoenzyme published in 2012 (Lolli et al., 2012): in this article autophosphorylation and 
the tendency to form aggregates of CK2, are in accordance with the trimeric organization 
of the butterfly shaped tetramers found in the crystal packing of the 4DGL structure. In 
this trimeric organization the autophosphorylation sites are really close to the catalitic 
cleft of CK2α coming from neighboring tetramers, the surface of interaction within the 
three tetramers is very extended and composed mainly of electrostatic interaction (in 
accordance with the low ionic strength-dependence of polymerization) and the ring like 
shape and the piling organization within the crystal can well describe the different 
oligomeric forms found with electron microscopy images. The beta subunits play a 
crucial role in this super-molecular organization, because the main contact within the 
tetramer is the acidic loop-basic stretch interaction between different tetramers. In this 
polymeric organization CK2 is supposed to be completely inactive due to steric hindrance 
of the catalytic cleft of CK2α, by different elements coming from neighboring CK2β; this 
inhibition by polymerization has been also discussed in the past (Poole et al., 2005) with 
the conclusion that CK2 in vivo might be a “constitutive inactive” kinase that is 
stimulated by alterations of the ionic status and by polycationic activators. So recently the 
idea of a “constitutive active” kinase is changing with the new data about the auto-
inhibitory polymerization, but some points remain open to discussion: the small 
CK2α/CK2β interface and the asymmetry found in both of the CK2 structures keep open 
the question whether the tetramer is a stable complex or a non-obligate complex or simply 
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a transition state between isolated CK2α and CK2β subunits and order super-molecular 
aggregates (Figure 2.22). 
 
1.3.4 CK2 inhibition  
The interest in developing small molecules that can act as kinase inhibitor has 
grown enormously since the first project started by Novartis 25 years ago, not only in the 
pharmaceutical industry but also in the academic research. In fact these small molecules 
can be useful also for studying many cellular pathways, like signal transduction, cell 
cycle regulation, development, apoptosis and others (Hemmings et al., 2009). Nowadays 
protein kinases (codified by the 2% of the genome) are the second most important drug 
targets after the G-protein-coupled receptor, and they represent the 20-30% drug 
discovery project in pharmaceutical companies (Hemmings et al., 2009). Targeting 
kinases with drug inhibitor molecules is not interesting just because kinases are usually 
related to cancer development, but also because they are implicated in different kind of 
pathologies as well: for example kinases are implicated in the inflammatory response, 
autoimmune disease and neurodegenerative disease. 
As described before, CK2 is essential for viability and it is implicated in different 
kind of biological pathways, so it can be considered a potential drug target for cancer 
therapy on the basis of different evidences: CK2 activity is elevated in several cancer 
cells, it is a potent suppressor of apoptosis promoting the survival of the cell and it 
promotes the multi-drug resistant phenotype (Battistutta, 2009). Recently CK2 has been 
discovered to be involved in neurodegenerative disease like Alzheimer’s disease and 
Parkinson’s disease but also in viral infection, because virus uses CK2 for the 
phosphorylation of some fundamental exogenous proteins, and in inflammation and 
cardiovascular diseases; for these reasons the development of CK2 inhibitors acts in 
different pharmacological fields, with a multi-potential perspective.  
Within the kinase family there is a conservation of many different structural 
elements, and part of this is the ATP binding site; to complicate the scenario there are 
other proteins inside the cell that are able to bind ATP. Another problem is the high 
concentration of ATP inside the cell (1-10 mM) that competes with the inhibitors for the 
binding to the kinase. Fortunately even if the catalytic cleft is globally conserved from the 
structural point of view, small differences at the level of single amino acids substitutions 
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are able to confer the possibility of an efficient and selective drug design with the result 
that many ATP-competitive kinase inhibitors (more than 130) are now in clinical trials 
(Fabbro et al., 2012). The selectivity of an inhibitor is therefore fundamental and it is 
actually the most difficult issue to achieve; anyway it has been proposed that the absolute 
selectivity for one single target is not a mandatory requirement for kinase inhibitor that 
aims to become a useful target. This is due to the fact that in cancer the pathways that 
promote proliferation and survival, are regulated not by a single kinase but by different 
kinases, comprising CK2, and therefore inhibiting different kinases at the same time 
seems a promising approach for cancer treatment. This concept of “one drug - many 
targets” having some non-specific effect on other kinases, has recently attracted the 
attention not only for inhibitor of kinases but also for other kind of drugs (Imming et al., 
2006). 
 
1.3.4.1 ATP-competitive inhibitors 
The ATP-binding site of protein kinase can be divided into three hydrophobic 
(adenine region and hydrophobic region I and II) and two hydrophilic regions (sugar 
pocket and phosphate binding region) (Fig. 1.21). ATP-competitive inhibitors are divided 
in two different classes: Type I and Type II. The Type I inhibitors target the protein in its 
active conformation (DFG-in conformation of the activation loop) and bind preferentially 
in the hydrophobic region of the adenine. These kinds of inhibitors are actually the most 
common inhibitors currently available for kinase inhibition and also for CK2. Type I 
inhibitors usually interact with the hinge region of the kinase and make hydrogen bounds 
with the backbone of the residues miming the interaction with the amino group of the 
adenine ring of the ATP. Type II inhibitors on the other hand bind to the inactive state of 
the protein kinase (DFG-out conformation of the activation loop) but have also contacts 
with the hinge region of the kinase (Battistutta, 2009). 
 
1.3.4.2 Structural aspect of inhibition by Type I ATP-competitive 
inhibitors  
CK2 bears most of the common sequence and structural features conserved during 
the evolution and found in most of the other kinases of the human kinome. The only two 
differences found in the primary sequence for the CK2 are the missing of a conserved 
third glycine in the phosphate-anchor loop, residues 46-51 GXGXøG (usually the ø is a 
1.3. CK2 
34 
tyrosin or a phenylalanine like for the Pim kinase) and the substitution of the conserved 
DFG triplet, at the beginning of the activation segment, with a tryptophan (W176) instead 
of the phenylalanine. Another important feature of the primary sequence of CK2 is the 
presence of a basic cluster at the beginning of the helix αC (resides 74-80) where 6 of the 
7 amino acids are basic residues.  
CK2 is an constitutive active kinase, because of its unique structural features, so 
only the active conformation of the kinase can be tagged with ATP-competitive inhibitors 
and as a consequence only the Type I inhibitor are available for CK2. They establish 
direct polar interaction with a limited, conformationally rigid, portion at the N-terminal 
part of the hinge/αD region (backbone of residues Glu114 and Val116) and/or with the 
deeper part of cavity, principally with some conserved water and with the lysine 68. A 
recent analysis of the flexible region of the protein showed that ligands that don not use 
the hinge/αD region for the binding to the protein would, at least in principle, bind in the 
same way to the CK2 with an open (like CK2 maize enzyme) or close conformation of 
the hinge region. This concept has been demonstrated for two CK2 inhibitors like emodin 
(1,3,8-trihydroxy-6-methyl-antraquinone) and for quinalizarin (1,2,5,8-tetrahydroxy-
anthraquinone) (Figure 1.11), which have been crystallized with an open and a close 
conformation of the hinge/αD region: both of the inhibitors bind in the same way to the 
kinase with an open or close conformation of the hinge/αD region (Papinutto et al., 2012). 
The overall structure of the protein is only marginally affected by the binding of the 
inhibitor, with the C-lobe of the protein poorly influenced by the complex formation, and 
with N-lobe of the protein which has a much higher degree of flexibility in particular on 
the phosphate anchor loop. The other regions which have a structural plasticity are the 
His160, the hinge/αD region and the stretch from residues 102 to residues 108 comprising 
the external loop between strands β4 and β5 (β4-β5 loop) (Papinutto et al., 2012). 
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Figure 1.11 Structural formulas of the principal CK2 inhibitors, grouped by chemical classes 
(Niefind et al., 2012). 
 
  
1.3. CK2 
36 
The binding site of CK2 is composed of the residues Leu85, Val95, Leu111, 
Phe113, and Ile174 (hydrophobic region I), Val53, Ile66, Val116 and Met163 (adenine 
region) and Val45 and Tyr115 (hydrophobic region II) (Figure 1.12); this hydrophobic 
surface of the CK2 binding pocket is fundamental for the hydrophobic interactions and 
van der Waals contacts with the small ligand, which give the most important energetic 
contribution to the binding.  
 
 
Figure 1.12 Main structural features of the CK2α ATP-binding site shown in two different 
orientations. The active site is occupied by the CX-4945 inhibitor (cyan). Residues of the three 
hydrophobic regions common to the “kinase pharmacophore” are shown in yellow (hydrophobic 
region I, in the deepest part of the cavity), in orange (hydrophobic region II, at the entrance of the 
cavity) and in magenta (adenine region). Other important elements of the CK2α pharmacophore 
are the hinge region (dark red) and the area with a positive electrostatic potential near the salt 
bridge between Lys68 and Glu81, where the fully conserved water molecules w1 is located. These 
two regions are the main polar anchoring points for CK2 inhibitors (Niefind et al., 2012). 
 
The binding pocket of CK2 is smaller with respect to the other kinases, and this is 
due to the presence of some bulky side chains like Val66 and Ile174, which in the other 
kinases is replaced with a less cumbersome amino acids like alanine and leucine. For 
instance, the inhibitor TBB (4,5,6,7-tetrabromo-1-benzotriazole) binds in a different way 
to CDK2, which is a kinase belonging to the closely related CMGC group of the kinase 
family, with respect to CK2. This difference in binding is precisely due to the fact that the 
binding site of CDK2 is larger than CK2 because of the presence of alanine instead of the 
isoleucine 66 and 174, and as a consequence TBB shows an remarkable affinity for CK2 
(Figure 1.13). In particular in these kind of tetra-halogenobenzo derivates the bulkiness of 
the four halogen atoms is essential for the potency of the inhibitor with an increasing 
value upon the replacement of chlorine with bromine and even more with iodine. 
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Figure 1.13 TBB binds to CK2 (light grey) and CDK2 (dark grey) with different poses. Bulky CK2 
residues Ile66 and Ile174 are substituted with two alanines (31 and 144) in CDK2, whose active 
site results larger. The different shapes of the active sites determine the two diverse binding modes 
of TBB to the kinase (Niefind et al., 2012). 
 
An analysis of the electrostatic potential inside the catalytic site, revealed that 
there’s a positive charged region located in the deeply area of the cavity near the 
hydrophobic region I and the salt bridge between Lys68 and Glu81; for this reason if in 
the inhibitor is present a negatively charged moiety, like the acidic triazole ring of the 
TBB or the CX compounds, it tends to cluster in this region of the ATP-binding site. 
Another important feature of the deeper part of catalytic cleft is the presence of a 
conserved water molecule, called water molecule 1 (W1), which is present in all the CK2 
crystal structures published to date. It makes hydrogen bounds with the amidic NH of 
Trp176, with carboxylic oxygen of Glu81 and with another conserved water molecule 
(W2) which can be eventually replaced by a portion of a certain ligand (Emodin or CX 
compounds) (Figure 1.12). 
In general to be a good ATP-competitive inhibitor of CK2 a small ligand should 
have: an appropriate hydrophobicity to pass quickly from the aqueous phase to the 
hydrophobic site, an excellent shape complementary with the small and unique active site 
of CK2 and, most importantly, the capability to establish electrostatic interaction with the 
positive area near the W1 and hydrogen bounds with the possible anchoring points in the 
hinge region (Val116 and Glu114). 
To be useful as biochemical tools and to be considered compounds with 
pharmacological potential inhibitors must be cell permeable and active in cells. CX-4945, 
CX-5011, and CX-5279 all display cell permeability and high efficacy as antiproliferative 
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agents when tested on a variety of cancer cells (Pierre et al., 2011). Polyhalogenated 
benzimidazole (or triazole or pyrazole) derivatives, namely DMAT, TBB, TBI are all cell 
permeable and were among the most frequently used CK2 inhibitors for in vivo studies. 
However, there are other types of inhibitors, despite of their potency in vitro, which the 
practical use in vivo is hindered by deliverability problems, limiting their pharmacological 
potential and the possibility to use them as biochemical tools.  
The new concept of “one-drug many-targets” has been recently applied also for 
CK2 in the identification of difurandicarboxylic acid derivatives as potent dual inhibitors 
of this protein kinase and PIM kinases, two structurally and functionally related kinases. 
Crystal structures of CK2 and PIM1 complexes suggested that the basis of the selectivity 
of this class of compounds mainly relies on the narrower ATP-binding site of both CK2 
and PIM1, and particularly on the presence of two conserved isoleucine (Ile174 and Ile95 
in CK2, Ile185 and Ile104 in PIM1) (Lopez-Ramos et al., 2010). 
 
1.3.4.3 Non-ATP-competitive inhibitor (Type III Inhibitor) 
This kind of compounds do not target the active site of the protein but they’re able 
anyway to down regulate the activity of the kinase; examples of allosteric inhibitors, 
which display no contact with the hinge region, have been proposed also for CK2. The 
first Type III inhibitor for CK2 which was crystallized with CK2 is DRB: despite its ATP-
competitive activity, a second molecule of DRB was found in the hydrophobic cavity near 
the loop β4-β5, which is the main interacting zone for the CK2β for the holoenzyme 
formation. The binding of the DRB shows a non-competitive inhibitory effect that was 
discriminated from the ATP-competitive one (Raaf et al., 2008b), but more interesting the 
identification of this new binding site is important also for the possibility to selectively 
interfere with the assembly of the tetrameric enzyme (Figure 1.14).  
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Figure 1.14 Close-up view of the secondary (allosteric) binding site occupied by inhibitor DRB, 
in the N-terminal lobe of the α-subunit (shown as surface) (Niefind et al., 2012). 
 
Another recent example of non-ATP compound was design on the basis of the α/β 
interface of CK2, and it is composed of a cyclized peptide containing the sequence 
Arg186-His193 of the CK2β. This cyclic peptide is able to inhibit the formation of the 
holoenzyme and to affect the substrate preference (Laudet et al., 2007). Due to the lack of 
the crystal structure of this compound with the CK2α the exact mode of binding is 
unknown but presumably it binds in the same way of the CK2β C-terminal tail and also in 
the same area of interaction (like the linear peptide and the DRB). The DRB with the 
human CK2α and the linear peptide of the β-subunit are not the only molecules found in 
this allosteric site; in particular structures of human CK2α with other small ligands like 
PEG or ethylenglycol (Papinutto et al., 2012) or glycerol (Raaf et al., 2008b) have been 
reported. None of these structures shows significant conformational changes inside the 
active site that can be related to a modulation, either negative or positive, of the catalytic 
activity of the isolated CK2α and to date there are no clear explanation for the structural 
effects of the binding to the secondary “allosteric” site. 
The design of specific inhibitor of the α/β interaction is fundamental for the study 
of the assembly of the CK2 tetramer, inhibiting it in vivo and could be used as a tool in 
the study of the substrates which phosphorylation is dependent on the presence of CK2β. 
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1.4. Aim of the project 
Most of the knowledge related to the structural characteristics of CK2 has come 
from studies within the last fifteen years and the interest in this enzyme has expanded, as 
shown by the increasing number of publications within recent years. Despite the 
increasing interest in this protein, a substantial amount of research is needed to 
understand its mechanism of regulation in human physiology. The structural 
characterization is an essential step to understand how CK2 is regulated in all of the 
biological processes, which have been reported to be related with the kinase.  
Even if the structural knowledge of CK2 is very extended, very little is known 
about the C-terminus of CK2α and no high resolution 3D-structure is available for the 
full-length sequence. This region is supposed to be very flexible and non-structured in 
solution but it has been reported that CK2 can be phosphorylated in a cell cycle 
dependent manner at residues located in this C-terminal portion. 
Moreover no 3D structure of the tetrameric holoenzyme with the catalytic subunit 
CK2α’ is present in the literature. The paralog isoform of the catalytic subunit CK2α’, 
present in humans and higher animals, is very similar in sequence to the CK2α up to 
position 330, while the C-terminal segments differ completely in length and sequence. 
The knowledge on CK2α’ is much lower than the paralog isoform CK2α; the main 
reasons are the reported solubility problems that occur after the expression in hosts cells 
like E. coli or insect cells.  
To this purpose the first part of the PhD project focused on the production and 
crystallization of a stable full-length CK2α phosphomimetic mutant and a tetrameric 
holoenzyme with the same catalytic subunit, in order to study the possible structural role 
of the C-terminus. Using the same protocol we worked on the production and 
crystallization of other forms of tetrameric holoenzyme with the wild type full-length 
CK2α and with its C-terminus deleted form. 
The second part of the project concerned with the development of a protocol for the 
production of the holoenzyme with the CK2α’ subunit and the physiological chimeric 
holoenzyme composed of CK2α and CK2α’. We started with the full-length mouse CK2α’ 
conjugated with the GST tag which may increase expression and solubility of the 
recombinant fusion protein. 
A part of my PhD project focused on the interaction between CK2 and small ligand 
which can compete with the ATP for the binding to the kinase. In collaboration with the 
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laboratories of Professor Pinna and Professor Moro, we studied the interaction between 
the CK2α336 (deleted at residue Ser336) and a potent and selective Type I ATP-
competitive inhibitor, called K164. We worked on the crystallization condition of the apo 
form of CK2α336 which was fundamental for the obtaining of the structure of the complex 
between the ligand and the kinase. 
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2. CK2α phosphomimetic mutant and CK2 
holoenzyme CK2α2β2 
2.1 CK2α phosphomimetic mutant  
2.1.1 Methods 
2.1.1.1 Overview 
We know that CK2α subunit undergoes to phosphorylation by Cdk1 in a cell cycle 
dependent manner; the four phosphorylation sites are located in the C-terminal tail of the 
protein namely at Thr344 and 360 and Ser362 and 370. The only structural information 
present in the literature about the C-terminal tail is the structure of the O-GlcNAc 
transferase in complex with a peptide substrate composed of the c-terminal tail of the 
CK2 341PGGSTPVS*SANM352 (Figure 1.8). 
The C-terminal tail of CK2 is absent in all the structures published in the database 
because it was deleted by mutagenesis or by auto-proteolysis; the reason of this deletion 
is that the C-terminal tail is flexible in solution and shows a high degree of degradation 
which can give after the purification a non-homogeneous sample not suitable for the 
crystallization. For this reason, the first problem to overcome was obtaining a full-length 
protein with a low degree of degradation. 
To investigate if the phosphorylation of the four residues could have a structural 
role at the level of the CK2α monomer or at the level of the holoenzyme, we mutated the 
four residues in four glutamic acids to mimic the negative charges of the phosphate 
group. 
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CK2α            MSGPVP-SRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINI 59 
CK2α’           MPGPAAGSRARVYAEVNSLRSREYWDYEAHVPSWGNQDDYQLVRKLGRGKYSEVFEAINI 60 
                *.**.. ******::**: *.*******:** .*************************** 
 
CK2α            TNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNT 119 
CK2α’           TNNERVVVKILKPVKKKKIKREVKILENLRGGTNIIKLIDTVKDPVSKTPALVFEYINNT 120 
                ****:*****************:*********.***.* * ******:*******::*** 
 
CK2α            DFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLA 179 
CK2α’           DFKQLYQILTDFDIRFYMYELLKALDYCHSKGIMHRDVKPHNVMIDHQQKKLRLIDWGLA 180 
                ******* ***:********:********* ****************:::********** 
 
CK2α            EFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNY 239 
CK2α’           EFYHPAQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRREPFFHGQDNY 240 
                *****.*******************************************:******:*** 
 
CK2α            DQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALD 299 
CK2α’           DQLVRIAKVLGTEELYGYLKKYHIDLDPHFNDILGQHSRKRWENFIHSENRHLVSPEALD 300 
                *************:**.*:.**:*:***:******:*******.*:****:********* 
 
                                                            *        
CK2α            FLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSSSMPGGSTPVSSANMMSGISSVP 359 
CK2α’           LLDKLLRYDHQQRLTAKEAMEHPYFYPVVKEQS--------------------------- 333 
                :**********.****:*********.***:*:                            
 
                * *       * 
CK2α            TPSPLGPLAGSPVIAAANPLGMPVPAAAGAQQ 391 
CK2α’           -----QPCADNAVLSSG------LTAAR---- 350 
                      * *...*:::.      :.**      
 
Figure 2.2.1 Multiple sequence alignment of selected CK2 alpha and alpha prime ClustalW tool, 
EMBL-EBI. C-terminal tail is highlighted in the squares and C-terminal peptide in complex with 
O-GlcNAc transferase is highlighted in yellow. 
 
2.1.1.2 Mutagenesis 
Single-site mutagenesis was performed using QuickChange Site-Directed 
Mutagenesis kit (Stratagene) and PfuTurbo DNA polymerase. 
Table 2.1 Oligonucleotide primers used for mutagenesis 
Single-site 
mutagenesis 
Primers base Tm (°C) 
T360E-S362E 5' gggatttcttcagtgccaGAGcctGAaccccttggacctctggc 
3' ccctaaagaagtcacggtCTCggaCTtggggaacctggagaccg 
44 79.3 
T344E 5' ccagggggcagtGAgcccgtcagcagc 
3' ggtcccccgtcaCTcgggcagtcgtcg 
27 79.8 
S370E 5' ggacctctggcaggcGAaccagtgattgctgc 
3' cctggagaccgtccgCTtggtcactaacgacg 
32 79.8 
 
MIX: 2.5 μl reaction buffer, 2 μl of plasmid containing the sequence of CK2α, 4.5 
μl of each primers (4.5 pmol), 0.5 μl of dNTPs, 11.0 μl of H2O, 0.5 μl of PfuTurbo DNA 
polimerase (2.5 U/μl). After 16 PCR cycles we add 1 μl of Dpn I restriction enzyme (10 
U/μl) for the digestion of non-mutated DNA. 
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The mutations have been inserted in the order of table above and after every 
mutagenesis we sequenced the DNA. 
 
2.1.1.3 Protein expression 
E. coli BL21(DE3) cells, harboring the plasmid pT7-CK2α phoshomimetic, were 
grown overnight (ON) at 37 °C in LB medium (10 g/l tryptone, 5 g/l yeast extract, and 10 
g/l NaCl) supplemented with 50 μg/ml ampicillin. LB medium was inoculated with this 
ON culture (ratio 1:10) and grown at 37 °C, in a suitable shaker. Protein expression was 
induced at an OD600 of 0.6 by adding 1 mM IPTG and prolonged for 4-5 h at 30 °C under 
vigorous shaking. Bacteria were harvested by centrifugation at 5000 g for 30’. 
 
2.1.1.4 Protein purification 
In order to obtain a stable CK2α full-length protein we proceeded with a very fast 
protocol of purification with two purification steps performed in the same day; in this way 
the protein passed from the bacterial cytoplasm to the final buffer C (with a purity of ≈ 
95%) and storage at -80 °C in only 8 hours avoiding C-terminal degradation. Bacteria 
were suspended in buffer A [25 mM Tris-HCl (pH 8), 350 mM NaCl, 1 mM dithiothreitol 
(DTT)] supplemented with protease inhibitors (Roche) and lysed with a French press 
(Thermo Spectronic) at high pressure. 
The lysate was centrifuged to remove cell debris at 27000 g for 30’ and filtered with 
0.22 μm syringe filter. After the filtration the sample is loaded onto an affinity column 
performed on a Äkta FPLC chromatographic system (GE Healthcare) using a HiTrap 
Heparin HP 5ml (GE Healthcare) equilibrated with buffer A. After extensive washing 
with buffer A, the protein was eluted with a gradient of NaCl with buffer B [25 mM Tris-
HCl (pH 8), 1 M NaCl, 1 mM DTT]. Fractions containing the protein were pooled and 
further purified by size exclusion chromatography using a Superdex 75 prep-grade 26/60 
column (GE Healthcare) equilibrated with buffer C [25 mM Tris-HCl (pH 8.5), 500 mM 
NaCl, and 1 mM DTT]. 
 
2.1.1.5 Protein crystallization 
Crystallization trials using commercial kits (Qiagen, Molecular Dimensions and 
Hampton Research) based on sparse matrix, grid screen, and/or ionic sampling, were 
2.1.1. Methods  
46 
performed by vapour diffusion (with the sitting drop method) techniques, using the Oryx8 
automatic system (Douglas Instrument). CK2α phosphomimetic mutant was concentrated 
to 15 mg/ml for crystallization purposes. Thin and fragile crystals were grown at 20 °C, 
using the following precipitant solution: 0.2 M ammonium acetate, 0.1 M tri-sodium 
citrate pH 5.6, 30% w/v PEG 4000. 
 
2.1.1.6 Data collection, structure determination, and refinement 
The data set at 3.3 Å resolution was collected at the ELETTRA-Synchrotron 
beamline XDR1, (Trieste, Italy). Data sets were measured at 100 K using the precipitant 
solution, including 10% glycerol as cryoprotectant. Crystals belonged to space group 
P43212, with unit cell parameters reported in Table 2.2. Diffraction data were processed 
with XDS (Kabsch 2010) and reduced and merged with SCALA included in the CCP4 
suite (Evans, 2005). For structure determination, molecular replacement (Phaser CCP4) 
(McCoy et al., 2007) was performed with the coordinates of the CK2αdel from PDB ID 
3BQC. The model was then refined alternating several cycles of automatic refinement 
with REFMAC (CCP4) (Murshudov et al., 1997) and manual model building with Coot 
(Emsley and Cowtan, 2004). 
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2.1.2 Results 
2.1.2.1 Mutagenesis 
In order to mimic the negative charges of the four phosphorylated residues at the C-
terminal tail of the CK2α (Thr344, Thr360, Ser362, Ser370), we mutated the four residues 
in glutamic acids by single-site mutagenesis; the success of the experiment was confirmed 
by DNA sequencing after each PCR. The primary sequence of the CK2α clone after the 
third experiment of mutagenesis confirmed the presence of the four mutations (the 
mutated codons that encode for glutamic acids are highlighted in yellow): 
 
                                                             344 
CK2α mut          GGACCAGGCTCGAATGGGTTCATCTAGCATGCCAGGGGGCAGTGAGCCCGTCAGCAGCG 
                  |||||||||||||||||||||||||||||||||||||||||||  |||||||||||||| 
CK2α wt           GGACCAGGCTCGAATGGGTTCATCTAGCATGCCAGGGGGCAGTACGCCCGTCAGCAGCG 
 
                                                  360   362 
CK2α mut          CCAATATGATGTCAGGGATTTCTTCAGTGCCAGAGCCTGAACCCCTTGGACCTCTGGCA 
                  ||||||||||||||||||||||||||||||||   |||  ||||||||||||||||||| 
CK2α wt           CCAATATGATGTCAGGGATTTCTTCAGTGCCAACCCCTTCACCCCTTGGACCTCTGGCA 
 
                     370 
CK2α mut          GGCGAACCAGTGATTGCTGCTGCCAACCCCCTTGGGATGCCTGTTCCAGCTGCCGCTGG 
                  |||  |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CK2α wt           GGCTCACCAGTGATTGCTGCTGCCAACCCCCTTGGGATGCCTGTTCCAGCTGCCGCTGG 
 
CK2α mut          CGCTCAGCAGTAA 
                  ||||||||||||| 
CK2α wt           CGCTCAGCAGTAA 
Figure 2.2 Multiple sequence alignment of CK2αwt and CK2αpm. 
 
2.1.2.2 Protein Expression and Purification 
CK2αpm (CK2α phosphomimetic mutant) was successfully expressed mainly in 
soluble forms in E. coli BL21(DE3) (Figure 2.3 lane 3). 
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Figure 2.3 Coomassie-stained SDS-PAGE of expression in BL21(DE3) of CK2αpm. Lane 1: not 
induced bacterial cells. Lane 2: IPTG induced cells. Lane 3: soluble portion of bacterial lysate. 
Lane 4: insoluble fraction of bacterial lysate. Lane 5: low molecular weight protein markers in 
kDa. 
The soluble fraction of CK2αpm protein was purified by an affinity step using a 
HiTrap Heparin column. The elution of the protein from the column was performed 
weakening the electrostatic interactions between CK2α and heparin molecules with a 
NaCl gradient. 
 
Figure 2.4 Elution profile of affinity chromatography of CK2αpm on column: HiTrap Heparin (GE 
Healthcare) equilibrated with buffer A [25 mM Tris-HCl (pH 8), 350 mM NaCl, 1 mM DTT]. 
Elution performed with increasing percentage of buffer B [25 mM Tris-HCl (pH 8), 1 M NaCl, 1 
mM DTT]. 
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Fractions of the main peak were loaded in a coomassie‐stained SDS–PAGE for 
identify the protein of interest (Figure 2.5). The fractions of the main peak showed a 
considerable level of impurities and also a probable degradation form exactly under the 
band of 45 kDa, which corresponds to the CK2αpm. To obtain a pure and homogenous 
sample we collected only the fractions corresponding to the first half of the main peak 
which showed a lower degree of contaminations. These fractions were than pooled in a 
second purification step represented by a size exclusion chromatography using a 
Superdex 75 prep-grade 26/60 column (GE Healthcare) equilibrated with buffer C, the 
final buffer of the purification. 
 
 
 
Figure 2.5 Coomassie‐stained SDS–PAGE after affinity chromatography. Lanes 1-8 correspond 
to fractions of the main peak of the chromatogram and lane 9 corresponds to low molecular 
weight protein markers in kDa. 
97 kDa 
66 kDa 
45 kDa 
30 kDa 
20 kDa 
14.4 kDa 
CK2αpm 
    1              2              3              4             5               6               7              8                             9 
2.1.2. Results  
50 
 
Figure 2.6 Elution profile of size exclusion chromatography with a Superdex 75 prep-grade 26/60 
column (GE Healthcare) equilibrated with buffer C [25 mM Tris-HCl (pH 8.5), 500 mM NaCl, 
and 1 mM DTT] 
The elution profile of the size exclusion chromatography showed a single slightly-
tailed peak; like for the step before, we loaded the fractions of the main peak in a 
coomassie‐stained SDS–PAGE for evaluate the purity level of the sample after the size 
exclusion chromatography.  
 
 
Figure 2.7 Coomassie‐stained SDS–PAGE after size exclusion chromatography. Lanes 1-9 
correspond to fractions of the main peak of the chromatogram and lane 10 corresponds to low 
molecular weight protein markers in kDa. 
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After the size exclusion chromatography the purity of the sample was high enough 
for the crystallization purpose. Under the main 45 kDa band, especially in the tail of the 
peak, there are some bands which correspond to degradation forms of the protein; even if 
we performed the purification with a fast protocol a small amount of protein underwent to 
proteolysis, probably losing the mutated C-terminal tail. We collected the fractions with a 
high purity of the sample, discarding the degraded forms, and the CK2αpm was 
concentrated to 15 mg/ml by ultrafiltration to a final yield of 12 mg per liter of culture. 
 
2.1.2.3 Protein crystallization 
We knew that CK2αdel gives good diffracting crystals under an optimized 
precipitant solution with 0.1 M Tris-HCl (pH 8.5), 0.2 Lithium Sulphate and 32% w/v 
PEG 4000 in P21 space group, and less-good diffracting form with 0.1 MES pH 6.5, 0.2 
Ammonium Sulphate and 22% w/v PEG 5000 MME in P43212 space group; because in 
CK2αpm we have 55 amino acids more than in the deleted form, we started from a sparse 
matrix screening, trying to obtain a new crystal packing with the entire visible C-terminal 
tail. After sever trails and optimization cycles we obtained a stick-shaped crystal under 
the following precipitant solutions: 0.2 Ammonium Acetate, 0.1 Tri-Sodium Citrate (pH 
5.6) 30% w/v PEG 4000. 
 
 
Figure 2.8 Crystals of CK2αpm in 0.2 Ammonium Acetate, 0.1 Tri-Sodium Citrate (pH 5.6) 30% 
w/v PEG 4000. 
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Even if the crystals of CK2αpm were very fragile and very difficult to manipulate we 
were able to collect a data set at the ELETTRA-Synchrotron beamline XDR1 (Trieste, 
Italy). 
 
2.1.2.4 Structure determination 
The structure was solved by molecular replacement using the structure of the 
CK2αdel 3BQC. Statistics on data collections and refinement are reported in table 2.2. 
CK2αpm crystallized in the space group P43212, like the CK2α
del
 with precipitant solution 
at pH 6.5 mentioned above; we were not able to obtain a new crystal form of the enzyme, 
and the overall structure of the enzyme within the crystal packing is identical to the 
published CK2αdel. Even if the quality of the data was not ideal and the refinement is not 
finished yet, the information found in the structure was sufficient for our purpose. 
 
Table 2.2 Data collection and refinement statistics 
Data collection statistics ELETTRA beamline XDR1, =1 Å 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
126.74  126.74  124.27 
90.00   90.00   90.00 
Total number of observations 83931 (10862) 
Total number of unique 15571 (2192) 
Resolution (Å) 56.68 (3.30) 
Rmerge (%) 0.355 (1.054) 
Rmeas (%) 0.393 (1.172) 
I/σ(I) 4.9 (1.8) 
Completeness (%) 98.8 (97.9) 
Multeplicity 5.4 (5.0) 
Refinement statistics 
Rwork (%) 0.25971 
Rfree (%) 0.30963 
The values in brackets are referred to the highest resolution shell. 
 
2.1.2.5 CK2αpm structure 
From the data collected we were able to solve and analyze the first structure of 
CK2αpm with the entire C-terminal tail. The following considerations can be taken after 
the analysis of the data: 
 We were able to crystallize the full-length form CK2α with four mutations on the 
C-terminal tail; 
 The packing within the crystal is the same of the other published CK2αdel in 
2.1. CK2α phosphomimetic mutant 
53 
P43212 and the overall folding of the kinase is identical to the other Ck2α
del
 
structures; 
 Although the electronic density is well defined in the major part of the structure, 
the last 59 residues are not visible and there is not free more electron density after 
the residue Ala332; so the C-terminal tail remains flexible and not visible in the 
crystal structure. 
Moreover, the not-so-good data collected, relating to maximum resolution and 
statistics, means a not homogenous sample within the crystal. This is probably due to the 
presence of the entire C-terminal tail which is flexible and disordered in solution and 
within the crystal. Even if we were not able to find a structural role for the entire 
phospho-mutant C-terminal tail, we optimized a fast purification protocol for obtain the 
full-length form of the CK2α enzyme; we used this for the further CK2 holoenzyme 
purifications, because we wanted to understand whether the C-terminal tail could had a 
structural significance within the holoenzyme form. 
 
Figure 2.9 (A) Overall structure of the CK2αpm in tetragonal crystal system P43212. (B) Detail of 
the electron density of the C-terminal tail: no more free electron density after the residue Ala332. 
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2.2 CK2 holoenzyme CK2α2β2 
2.2.1 Methods 
2.2.1.1 Overview 
The holoenzyme form of the protein kinase CK2 is composed of two catalytic α (or 
α’) subunits and two regulatory β subunits organized in a tetrameric form. Two structures 
are present in the database showing the architecture of the complex and how the subunits 
interact between each other; both of these structures lack completely the C-terminal tail of 
the α subunit. What we wanted to know was whether the C-terminal tail, which is flexible 
in solution and undergoes rapidly to auto-proteolysis during the purification, could have a 
structural role in the tetrameric holoenzyme. Again the first step was to find a way to 
obtain a stable CK2 holoenzyme with the entire C-terminal tail and then try to crystallize 
it. We actually were able to produce a stable form of the enzyme, with the same fast 
procedure of purification, and we crystallized three different forms of CK2 holenzyme 
namely the CK2 holoenzyme with the wild type full-length CK2α (CK2wt), the CK2 
holoenzyme with the phoshomimetic mutant of CK2α (CK2pm) and the CK2 holoenzyme 
with the deleted form of the CK2α (CK2del). 
 
2.2.1.2 Protein expression 
E. coli BL21(DE3) cells, harboring the plasmid pT7-CK2β were grown overnight 
(ON) at 37 °C in LB medium (10 g/l tryptone, 5 g/l yeast extract, and 10 g/l NaCl) 
supplemented with 50 μg/ml ampicillin. LB medium was inoculated with this ON culture 
(ratio 1:10) and grown at 37 °C, in a suitable shaker. Protein expression was induced at an 
OD600 of 0.6 by adding 1 mM IPTG and prolonged for 4-5 h at 30 °C under vigorous 
shaking. Bacteria were harvested by centrifugation at 5000 g for 30’. 
 
2.2.1.3 Protein purification 
Bacteria were suspended in buffer A [25 mM Tris-HCl (pH 8), 300 mM NaCl, 0.4 
mM (tris(2-carboxyethyl)phosphine) (TCEP)] supplemented with protease inhibitors 
EDTA free (Roche) and lysed with a French press (Thermo Spectronic) at high pressure. 
The lysate was centrifuged to remove cell debris at 27000 g for 30’ and filtered with 
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0.22 μm syringe filter. After the filtration we added CK2αwt, CK2αpm or CK2del (250 μl at 
15 mg/ml for 2.5 l of CK2β culture) and we left the lysate incubate for 10 minutes at 4 
°C. After the formation of the complex the sample is loaded onto an affinity column 
performed on a Äkta FPLC chromatographic system (GE Healthcare) using a HiTrap 
Heparin HP 5ml (GE Healthcare) equilibrated with buffer A. After extensive washing 
with buffer A the protein was eluted with a gradient of NaCl with buffer B [25 mM Tris-
HCl (pH 8), 1 M NaCl, 0.4 mM TCEP]. Fractions containing the protein were pooled and 
further purified by size exclusion chromatography using a Superdex 200 prep-grade 26/60 
column (GE Healthcare) equilibrated with buffer C [25 mM Tris-HCl (pH 8.5), 500 mM 
NaCl, and 0.2 mM TCEP]. The two step of purification were performed in the same day 
getting the sample always in ice to avoid the auto-proteolysis of the C-terminal tail as 
previously described for the CK2αpm. 
 
2.2.1.4 Dynamic light scattering 
DLS data were recorded on a Zetasizer NanoS instrument (Malvern Instruments 
Ltd.) at 20 °C, using a quartz cuvette and 20 μl of sample. Protein solutions were filtered 
using 0.22 μm filters. The data were recorded and analyzed with the Dispersion 
Technology Sofware (Malvern). 
 
2.2.1.5 Analytic gel filtration analysis 
Gel filtration chromatography can be used to calculate the molecular weight of a 
protein from its elution volume. Performed on an Äkta FPLC chromatographic system 
(GE Healthcare) we used a Superdex 200 10/300 GL column which is a prepacked gel 
filtration column for high-resolution, semipreparative and analytical separations of 
biomolecules. Superdex 200 has a separation range for molecules with molecular weights 
between 10000 and 600000 Da. We used thyro Globulin (699 kDa), Ferritin (440 kDa), 
Catalase (232 kDa), BSA (67 kDa), Oval Bumin (43 kDa) and Ribonuclease (13.7 kDa) 
for the calculation of a calibration line. 
 
2.2.1.6 Protein crystallization 
Crystallization trials using commercial kits (Qiagen, Molecular Dimensions and 
Hampton Research) based on sparse matrix, grid screen, and/or ionic sampling, were 
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performed by vapour diffusion (with the sitting drop method) techniques, using the Oryx8 
automatic system (Douglas Instrument). CK2 holoenzymes were concentrated to 8 mg/ml 
for crystallization purposes. Crystals were grown at 20 °C, using the following precipitant 
solution: 0.2 M ammonium citrate, pH 6.5, 20% w/v PEG 3350. 
 
2.2.1.7 Data collection, structure determination, and refinement 
The three data set were collected at the ELETTRA-Synchrotron beamline XDR1, 
(Trieste, Italy) and at European Synchrotron Radiation Facility beamline ID23-2 gemini 
(ESRF Grenoble, France). Data sets were measured at 100 K using the precipitant 
solution, including 20% glycerol as cryoprotectant. Full length CK2 crystals, 
phosphomutant or wild type, belonged to space group P21 and the crystal of the deleted of 
CK2 belonged to the space group C2, with unit cell parameters reported in Table 2.3. 
Diffraction data were integrated with XDS (Kabsch, 2010) and reduced and merged with 
SCALA included in the CCP4 suite (Evans, 2005). For structure determination, Rigid 
Body Refinement (CCP4) was performed with the coordinates of the wt CK2α from PDB 
ID 3BQC and with the coordinates of CK2β subunit PDB ID 3EED for the β2 dimer. The 
model was then refined alternating several cycles of automatic refinement with REFMAC 
(CCP4) (Murshudov et al., 1997) and manual model building with Coot (Emsley and 
Cowtan, 2004). Finally also the TLSs (Translation/Libration/Screw parameterization) 
were added. Statistics of the refinements and final models are reported in Table 2.3. 
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2.2.2 Results  
2.2.2.1 Protein expression and purification 
For obtain a stable form of the holoenzyme (CK2
wt
, CK2
pm
 or CK2
del
) we expressed 
the CK2β in E. coli BL21(DE3) and we added previously purified CK2αs (CK2αwt, 
CK2αpm or CK2αdel) to the filtrated lysate; after the incubation under ice for 10 minutes 
we loaded the sample in a HiTrap Heparin column for the first affinity purification step. 
The elution of the protein from the column was performed in the same way described for 
the CK2αpm, with a gradient of NaCl; in this way only the CK2β dimer which had formed 
a stable complex with the CK2α subunit would bind to the column due to the affinity 
between the catalytic subunit and the heparin molecules. 
 
 
Figure 2.10 Elution profile of affinity chromatography of CK2 holoenzyme on column: HiTrap 
Heparin (GE Healthcare) equilibrated with buffer A [25 mM Tris-HCl (pH 8), 300 mM NaCl, 0.4 
mM TCEP]. Elution performed with increasing percentage of buffer B [25 mM Tris-HCl (pH 8), 1 
M NaCl, 0.4 mM TCEP]. 
 
The chromatogram reported regards the elution profile for the holoenzyme with the 
CK2αpm form, but the same trend was found for the other holoenzyme complexes. 
Fractions of the main peak were loaded in a coomassie‐stained SDS–PAGE: 
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Figure 2.11 Coomassie‐stained SDS–PAGE after affinity chromatography. Lanes 1-9 correspond 
to fractions of the second main peak of the chromatogram and lane 10 corresponds to low 
molecular weight protein markers in kDa. 
The SDS-PAGE confirmed that the complex between CK2α and CK2β2 was 
formed, because they are both present in the gel, and that CK2α was able to bind to the 
heparin molecules without interfering with the bounded CK2β2 dimer. As in the 
purification of the single CK2αpm, this first step of purification was not sufficient for 
getting a pure sample and lots of impurities were present in the fractions of the main 
peak; so we proceeded with a second size exclusion chromatographic step: 
 
 
Figure 2.12 Elution profile of CK2α2β2 from size exclusion chromatography with a Superdex 200 
prep-grade 26/60 column (GE Healthcare) equilibrated with buffer C [25 mM Tris-HCl (pH 8.5), 
500 mM NaCl, and 0.2 mM TCEP] 
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The elution profile of the CK2 holoenzyme showed two peaks; to understand 
whether the proteins that cause the peaks were CK2α and CK2β we loaded the fractions 
of two peaks in a Coomassie‐stained SDS–PAGE. 
 
 
Figure 2.13 Coomassie‐stained SDS–PAGE after size exclusion chromatography. Lanes 1-8 
correspond to fractions of the main peak of the chromatogram and lane 9 corresponds to low 
molecular weight protein markers in kDa. 
 
From the SDS-PAGE we could confirm that the two peaks were composed of CK2α 
and CK2β proteins bounded together because both of them were present in all of the 
fractions. The size exclusion crhomatogrphy separates the proteins by their molecular 
weights and we knew that CK2β2 can bind at most two CK2αs; in this case it seemed that 
there were two different forms of CK2 holoenzymes, composed both of CK2α and CK2β 
subunits, that segregates at two different elution volumes due to their different molecular 
weights. Firstly, we tried to separate the two species (“first peak” and “second peak”) and 
reloaded in the same size exclusion chromatography to understand whether there was a 
dynamic equilibrium between the two CK2 forms. From the chromatogram reported in 
figure 2.7 we understood that the two species are stable and do not interconvert in each 
other when they are isolated. The stability of the two CK2 holoenzyme forms permitted 
us to work on the characterization of the two macromolecules, in particular using 
techniques that could be useful to elucidate whether this double peak was due to different 
form of aggregation or to a different stoichiometry of binding between CK2 subunits. 
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Figure 2.14 Elution profile of size exclusion chromatography with a Superdex 200 prep-grade 
26/60 column (GE Healthcare); in blue the “second peak” reloaded in the column, in red the 
“first peak” reloaded in the column and in green the double in peak reported for comparison. 
 
2.2.2.2 Dynamic light scattering 
For the quantification of the molecular weight and for the analysis of the protein 
behavior in solutions, the two species were analyzed by Dynamic Light Scattering (DLS). 
The particle size distribution by intensity of the two CK2 forms is reported in Figure 2.15; 
the main form in solution for the “first peak” is the monomeric form while for the 
“second peak” high molecular weight aggregates are present in addition to the monomeric 
form. The presence of these aggregates is usually a symptom of a not good behavior of 
the sample in solution and usually indicates that the sample is not suitable for 
crystallization purpose. From the DLS analysis we got information about the size of the 
two spices; in particular the “first peak” has a calculated diameter of 12 nm which 
corresponds circa to a 220 kDa molecule and the “second peak” has a calculated diameter 
of 9 nm which corresponds to a 120 kDa molecule. DLS analysis confirmed the data of 
the first size exclusion chromatography that the two species are stable in solution and one 
(“first peak”) has a diameter, and so as a consequence a molecular weight, bigger than the 
other one (“second peak”). 
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Figure 2.15 Particle size distribution by intensity of (RED) CK2 holoenzyme “first peak” and of 
(GREEN) CK2 holoenzyme “second peak”. The proteins concentration was 1 mg/ml in 25 mM 
Tris-HCl, 500 mM NaCl and 0.2 mM TCEP (pH 8.5). 
 
2.2.2.3 Analytic gel filtration analysis 
To have a more precise valuation of the molecular weight of the two species we 
performed an analytic gel filtration chromatography with a Superdex 200 10/300 GL 
column which is a prepacked gel filtration column for high-resolution analytical 
separations of biomolecules. We used a mixture of six different proteins as standards to 
calculate the calibration line: 
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Figure 2.16 Elution profile of analytical size exclusion chromatography with a Superdex 200 
10/300 column (GE Healthcare); in cyan the elution profile of the mix of standards composed of 
Thyro Globulin (699 kDa), Ferritin (440 kDa), Catalase (232 kDa), BSA (67 kDa), Oval Bumin 
(43 kDa) and Ribonuclease (13.7 kDa), in red the elution profile of the “first peak”, in green the 
elution profile of the “second peak” and in magenta the elution profile of the CK2del with the two 
species still mixed together. 
 
From the calibration line calculated we were able to evaluate the following 
molecular weights for the two CK2 holoenzyme forms: 
 CK2 full-length (CK2wt or CK2pm) 
- 230 kDa for the “first peak” 
- 137,5 kDa for the “second peak” 
 CK2del 
- 154 kDa for the “first peak” 
- 111 kDa for the “second peak” 
We noticed that there was a great difference between the calculated molecular 
weight for the CK2 holoenzyme with the C-terminal tail (CK2
wt
 and CK2
pm
) and the CK2 
holoenzyme without it (CK2
del
); the C-terminal 55 amino acids have a molecular weight 
of 5.16 kDa and could unlikely explain the gap between the “first peaks” where the 
difference in terms of calculated molecular weight was 76 kDa (230 kDa and 154 kDa). 
Another interesting thing was the difference of molecular weights between first and 
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second peak of the full-length CK2 holoenzyme: 93 kDa couldn’t be easily explained by 
the addition of a single CK2α (45 kDa) or a CK2β2 dimer (50 kDa). The explanation of 
this phenomenon come from the molecular weight difference between first and second 
peak of the CK2
del
 holoenzyme: in this case the gap was 44 kDa and it could well fit with 
the molecular weight of a single CK2αdel molecule (40 kDa). We than hypothesized that 
the “first peak”, for both full-length CK2 and CK2del holoenzyme, could correspond to 
the tetrameric form of the kinase CK2α2β2, and the “second peak” could correspond to a 
trimeric form, namely CK2αβ2. This hypothesis was confirmed by the addiction of free 
CK2α’ to the “second peak” of the full-length CK2 holoenzyme: the result was a shifting 
of the elution volume to a value equivalent of the “first peak” (Figure 3.16). The meaning 
of this effect was that in the purification we didn’t saturate all the CK2β2 binding site for 
the CK2α, with a consequent double population of saturated tetrameric holoenzyme 
CK2α2β2 (“first peak”) and an incomplete trimeric form of CK2αβ2 (“second peak”). 
Moreover we understood that the 55 amino acids of the C-terminal tail were able to 
increase the hydrodynamic volume of the full-length protein with an effect analogous to 
an apparent increase in the MW of 76 kDa with respect to the deleted form; this fact is 
probably due to the reported great flexibility of the C-terminal tail in solution. 
After these considerations we continued working with only the tetrameric form of 
the protein and we proceeded with the crystallization trials. 
 
2.2.2.4 Protein crystallization 
Like for all of the new proteins we started from crystallization trials using 
commercial kits based on sparse matrix with the Oryx8 automatic system (Douglas 
Instrument): with the robot we are able to make a crystallization plate in 20 minutes 
testing 96 different precipitant conditions at two different protein concentrations. All of 
CK2 holoenzymes were concentrated to 8 mg/ml for crystallization purposes. After more 
than 300 precipitant solution tested, we were able to individuate three best promising 
conditions which gave crystals of different sizes and shapes; figures below were taken 
from crystallization drops made by hand after 3 days of incubation mixing 1 μl of 
precipitant solution and 1 μl of protein solution concentrated to 8 mg/ml.  
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Figure 2.17 Crystals of CK2 holoenzyme obtained with precipitant solutions A [0.2 M NaCl, 0.1 
Hepes (pH 7.5), 10% v/v isopropanol], B [0.2 NaCl, 0.1 M Na/K (pH 6.2), 50% v/v PEG 200] 
and C[0.2M d-Ammonium Citrate (pH 5.5), 20% w/v PEG 3350]. 
All of the crystals above were tested at the ELETTRA-Synchrotron beamline 
XDR1, (Trieste, Italy) with a resolution limit of 12 Å for condition A, 6 Å for condition B 
and 4 Å for condition C. After the high-throughput screening we then started with the 
optimization procedure of the three best conditions; after several cycles of optimization 
we were able to individuate the best precipitant solution for obtaining a big and resistant 
CK2 holoenzyme crystal, which was composed of 0.2 M d-Ammonium Citrate (pH 6.5), 
20% w/v PEG 3350. This precipitant solution permitted us to crystalize (even if with 
some adjustments in precipitant’s concentrations) and solve the crystal structure of all the 
three forms of holoenzyme produced CK2
wt
, CK2
pm
 and CK2
del
. In Figure 2.18 the photo 
of the crystal of the CK2
pm
, taken at the European Synchrotron Radiation Facility 
beamline ID23-2 gemini (ESRF Grenoble, France), which was the first full-length CK2 
holoenzyme crystallized, collected and which structure was solved. 
 
Figure 2.18 Crystal of CK2
pm
 holoenzyme obtained with precipitant solution 0.2 M d-Ammonium 
Citrate (pH 6.5), 20% w/v PEG 3350, taken at the European Synchrotron Radiation Facility 
beamline ID23-2 gemini (ESRF Grenoble, France).. 
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2.2.2.5 Data collection, structure determination, and refinement 
We collected the dataset of the CK2
pm
 at European Synchrotron Radiation Facility 
beamline ID23-2 gemini (ESRF Grenoble, France) while the dataset or CK2
wt
 and CK2
del
 
were collected at the the ELETTRA-Synchrotron beamline XDR1, (Trieste, Italy): the 
microfocus beamline of the ID-23 permitted us to achieve the 3.1 Å resolution for the 
CK2
pm
, while for the other two holoenzymes the resolution is lower with 3.79 Å for the 
CK2
wt
 and 4 Å for the CK2
del
. The CK2 holoenzyme crystallized in monoclinic space 
groups (P21 in the presence of the full-length CK2α for CK2
wt
 and CK2
pm
 and C2 with 
truncated form of CK2α for CK2del). The crystal packing is very similar and the 
differences are to be ascribed to the additional space required for the CK2α C-terminus 
(CK2
wt
 and CK2
pm
) (Figure 2.19). In particular in the space group P21 two molecules for 
asymmetric unit are present, while in the space group C2 only one molecule for 
asymmetric unit.  
 
Table 2.3 Data collection and refinement statistics 
 CK2
pm
 CK2
wt
 CK2
del
 
Data collection 
statistics 
ESRF beamline ID23-
2 , =1 Å 
ELETTRA beamline 
XDR1, =1 Å 
ELETTRA beamline 
XDR1, =1 Å 
Cell dimensions 
a, b, c (Å) 
 
α, β, γ (°) 
P 1 21 1 
142.316, 57.958, 
86.188 
90.00, 102.42, 90.00 
P 1 21 1 
141.575, 58.085, 
185.568 
90.00 102.33 90.00 
C 1 2 1 
210.310, 58.340, 
140.600 
90.00 118.66 90.00 
Total number of 
observations 
278220 (40507) 80645 (7523) 28630 (4193) 
Total number of 
unique 
52811 (7775) 25159 (3590) 11387 (1680) 
Resolution (Å) 181.90 – 3.10 181.35 – 3.79 123.40 - 4 
Rmerge (%) 0.162 (0.643) 0.229 (0.337) 0.182 (0.574) 
Rmeas (%) 0.179 (0.715) 0.265 (0.427) 0.229 (0.723) 
I/σ(I) 10.2 (2.6) 4.1 (2.2) 4.3 (1.9) 
Completeness (%) 97.9 (98.7) 85.9 (85.0) 88.4 (89.8) 
Multeplicity 5.3 (5.2) 3.2 (2.1) 2.5 (2.5) 
Refinement statistics 
Rwork (%) 0.23 0.29 0.25 
Rfree (%) 0.26 0.32 0.26 
The values in brackets are referred to the highest resolution shell. 
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Figure 2.19 Crystal packing in monoclinic crystal system P21 (CK2
wt
 and CK2
pm
) and C2 
(CK2
del
). 
 
2.2.2.6 CK2 holoenzyme in monoclinic crystal systems 
In the two structures containing the full-length CK2α subunit (CK2wt and CK2pm) 
no appreciable density is present for the C-terminal tail. Like in the structure of the 
monomer CK2αpm, the C-terminal tail appears to be flexible and disordered in solutions 
and it is not visible in the crystal structure; the only effect that we were able to notice, due 
to the presence of the C-terminal tail, was the different crystal packing between the 
proteins with the 55 amino acids tail (P21 for CK2
wt
 and CK2
pm
) and without (C2 for 
CK2
del
). This fact confirms that the fast protocol for the purification of the full-length 
CK2α permitted us to obtain a non-degraded form of the protein we were able to obtain a 
stable full-length CK2 holoenzyme and to crystallize it; unfortunately the structural role 
of the C-terminal tail remains unknown but we surely added some important information 
that will be useful for the complete understanding of the CK2 regulation mechanism.  
As reported in the introduction, among protein kinases, CK2α displays a unique 
flexibility in its hinge region that can assume two major conformations (open or close) 
(Figure 2.20B). In the numerous structures of the isolated CK2α subunit, both the open 
and close conformations have been reported. In the available structures of the CK2 
holoenzyme, the hinge region was found in the open conformation, even when a mutation 
(Y125R in 4DGL) was inserted in order to interfere with such conformation. More 
precisely, in the close conformation F121 occupies a hydrophobic cavity that is instead 
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partially filled by Y125 in the open. Here we observe that in the structure containing the 
truncated CK2α (CK2del), the hinge region is kept open. In CK2wt and CK2pm, poor 
electron density defines the hinge region that appears to be highly flexible and possibly 
oscillating between the two conformations. Whether this phenomena is related to the 
presence of the C-terminal tail, which could interact with the hinge region and force it to 
oscillate between an open and close conformation, is difficult to say and may lead to 
speculations. We conclude that in the CK2 holoenzyme the open conformation of the 
hinge region is preferred over the closed one, which is instead more difficult to stabilize 
and isolate, and that in the presence of the full-length CK2α the hinge region oscillates 
between the two conformations.  
In the interaction area between CK2α and CK2β, we found in all of the three 
structures that the CK2β phenylalanine 190 adopts a different conformation with respect 
to the one published in 2001 (1JWH). This conformation is the same found in the last 
CK2 holoenzyme structure (4DGL) and validate this new conformation: the CK2β 
Phe190 fills the hydrophobic cavity of CK2α subunit, while in the old structure the 
Phe190 was exposed to the solvent (Figure 2.20 C, D). This new conformation of the 
Phe190 strengthens the interaction between CK2α and CK2β making it more stable with a 
more pronounced hydrophobic character. 
As reported before the CK2 holoenzyme crystallized in monoclinic space groups 
(P21 for CK2
wt
 and CK2
pm
, C2 for CK2
del
) and, apart from small differences in the crystal 
packing due to the presence of the C-terminal tail in the full-length CK2 holoenzymes, 
the tetrameric architecture is virtually identical in all monoclinic structures (average 
RMSD = 1.4 Å); but a structural and comparative analysis with the published crystal 
structures (1JWH and 4DGL) in the hexagonal crystal system, made it clear that our 
structures were different (average RMSD = 2.5 Å) (Figure 2.21 A). 
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Figure 2.20 (A) Crystal structure of the CK2 tetrameric holoenzyme in monoclinic system. (B) 
Double conformation of the hinge region with open conformation in black (CK2
del
) and the close 
conformation in orange (in CK2
wt
 and CK2
pm
 there is an equilibrium between the two 
conformations). (C) Phenylalanine 190 (yellow) adopts a different orientation from the 1JWH 
structure (black) in the contact area between CK2α (orange) and CK2β (yellow). (D) Detail of the 
CK2α-CK2β interaction interface where the new CK2β Phe190 (highlighted in purple) fills the 
cavity of CK2α (in orange) with respect to the old conformation where the Phe190 leans on the 
outer interface (yellow). 
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In the previously published 1JWH and 4DGL structures the α2β2 tetramer is 
asymmetric in the position of the α-chains with respect to the central stable β2 dimer, with 
two different α/β interfaces. In the description of the first CK2 crystallographic structure 
(1JWH), a relative rotation of 16.4º at one of the two α-β2 interfaces around an axis lying 
at the outer β-sheet surface of the N-terminal CK2α domain was reported (Figure 2.21 B). 
For this reason at one side of the β-dimer, the first α chain binds through an extended 
interface (960 Å
2
), while the other “rotated” interface on the opposite side is much 
smaller (770 Å
2
) (Figure 2.21 C). The authors reported an average interface of 832 Å
2
 and 
compared it with the average interface sizes of 1722 Å
2
 for permanent and of 804 Å
2
 for 
non-obligate protein complexes. They concluded that CK2 is a transient hetero-complex 
that, despite its spontaneous and stable nature in vitro, can dissociate in vivo. 
Unlike in space group P63, in monoclinic crystals tetramers show a different, 
symmetric architecture, and two very similar α/β interfaces (average RMSD = 2.5 Å). The 
new symmetric architecture is due to the movement of the C-terminal lobe of a single α-
chain, pivoting around the hinge region, towards the β-subunit (counter clockwise 
rotation in Figure 2.21 D). The asymmetric “distortion” of the structures in space group 
P63 is caused by the insertion of the acidic loop of one symmetric β-subunit (residues 55-
64) and of the C-terminus of another symmetric β-subunit in between of the two lobes of 
the α-chain (Figure 2.21 E). The same crystallographic contacts are not present on the 
opposite side of the tetramers, leaving the other α-subunit and its interface with the β 
dimer undistorted and similar to what found in symmetric tetramers in monoclinic 
crystals. Structures presented here display that the CK2 holoenzyme is much more stable 
than what predicted before. First, they all confirmed the tracing of residues 194-207 of the 
β-subunit (increasing the interface area with the α-subunit), reported in the 4DGL 
structure and corrected in respect to the 1JWH structure. Then, α/β interfaces are now 
very similar with a mean value of 1081 Å
2
. They are mostly hydrophobic, as indicated by 
the P-values of the solvation energy gain below 0.5 (around 0.1-0.15) (Krissinel and 
Henrick, 2007). As a matter of fact, relatively small interfaces in kinase complexes 
considered stable are not unusual. We compare CK2 (interface area >1000 Å
2
) with the 
closely related Cyclin-dependent kinases. Interface for the Cdk9/CycT complex is 960 
Å
2
, similarly also to the Cdk4/CycD complex (1125 Å
2
). These data are more in 
accordance with the very low dissociation constant of the tetrameric holoenzyme, whose 
value of 3.7 nM is typical of strong protein complexes. Moreover the CK2 holoenzyme is 
stable to up to 5 M urea (data not shown) and its dissociation is concomitant with 
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denaturation of the α-subunit.  
 
 
Figure 2.21 (A) Superposition of crystal structure of CK2 tetramer in monoclic crystal system 
(colored) with CK2 tetramer in hexagonal crystal system (black). (B) Superposition of the two α-
subunits of the tetramer in hexagonal system, showing the rotation axis lying at the outer β-sheet 
surface of the N-terminal CK2α domain. (C) Surface representation of the CK2 tetramer in 
hexagonal crystal system showing the rotation of 16.4° of the C-terminal lobe of the α’’ subunit 
(gray), with two different interfaces of interaction between α’-β2 (black and pink/purple) and α’’-
β2 (gray and purple/pink). (D) Symmetric CK2 tetramer in the monoclinic system with identic 
interaction area α’-β2 (yellow and cyan/blue) and α’’-β2 (pink and blue/cyan). (E) The asymmetric 
“distortion” of CK2 tetramer of the hexagonal system caused by the insertion of the acidic loop of 
one symmetric β-subunit (cyan) and of the C-terminus of another symmetric β-subunit (dark blue) 
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in between of the two lobes of the α-chain (orange). 
 
The presence of relatively small interfaces in the stable CK2 holoenzyme could 
have a functional significance, and be associated to a certain plasticity necessary to 
respond and adapt to external events like binding to other proteins. In Cdk9/CycT 
complex, for instance, binding to the HIV-TAT protein causes an 8.5º rotation of Cdk9 
relative to CycT. This is not the case in the Cdk2/CycA complex, whose large interface 
(1834 Å
2
) keeps the complex very rigid and not affected by the binding of additional 
proteins, as observed in the Cdk2/CycA/p27 complex. The distortion observed in the 
structure of the asymmetric holoenzyme can represent an example of what can happen 
when the enzyme interacts with some substrates. This structural plasticity of the 
holoenzyme, that is its aptitude to be temporary distorted from the more stable symmetric 
state, could also correlate with the property to interact with many different partners. Non 
interacting α and β subunits have been observed in cells (Theis-Febvre et al., 2005). This 
is not necessarily to be ascribed to an intrinsic hypothetical weakness of the complex, that 
disagree with the reported Kd value, the stability of the holoenzyme in vitro and with the 
crystallographic data reported here. As a consequence we hypothesized that the CK2 
tetramer formation is an obligate protein complex instead of a transient protein complex 
and that once the complex is formed the subunits cannot return to the free monomer state. 
This view of the CK2 holoenzyme formation fits well with the recently proposed 
mechanism of regulation by an auto-inhibitory polymerization (Lolli et al., 2012) and can 
be describe as follow: the free monomer α-subunits and the β2-dimer interact together to 
give the stable and symmetric CK2α2β2 tetramer. This symmetric butterfly shaped 
holoenzyme is the fully active form of the protein. In the cellular environment, the 
CK2α2β2 tetramers cooperatively self-organize in trimeric rings thus favouring the 
autophosphorylation of β, which in turn stabilizes the trimeric interaction. Due to a 
significant structural complementarity, trimers can pile one over another, giving rise to a 
polymerized form of CK2 that constitutes the latent, fully inactive form of this kinase. As 
for most protein kinases, CK2 activity is restored only upon necessity, in this case by a 
depolymerization process originating fully functional free symmetric tetramers. When 
CK2 activity is not necessary any more, the tetramer can come back to the trimer 
organization, to restore the pull of latent and inactive CK2. 
Instead, it can be hypothesized that association of the CK2 holoenzyme can be 
prevented in vivo by mechanisms such as the intervention of β-competitive-α-interacting 
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or α-competitive-β-interacting proteins, by differential α and β localization or transport 
mechanisms or by unbalanced expression (Theis-Febvre et al., 2005). Tetramer 
dissociation could be also induced by specific regulatory mechanisms. However, whether 
such regulatory switches exist is still debated.  
 
 
Figure 2.22 Schematic representation of the regulation mechanism proposed for CK2. Once the 
CK2 tetramer is formed by the stable interaction by regulatory β2-dimer (green) and α subunits 
(orange) it is in the fully active form; than it can undergo to auto-inhibitory polymerization 
mechanism first by forming trimer (inactive) and second by pilling organization of the trimers 
(inactive). This process of polymerization is reversible and the activity of CK2 can be restored 
upon necessity via depolymerisation mechanism. 
 
The unbalanced expression of the two subunits, with β being predominant, could 
lead to trimeric α β2 holoenzymes or to chimeric enzymes with the free β-subunits able to 
recruit the paralogue subunit α’ (in brain and testis where this last is expressed) or other 
kinases (A-raf, c-mos and Chk1 have all been reported to interact with the α-subunit 
possibly using the same binding mode observed for CK2α) or non-kinase partners. Here 
we report that in vitro a stable and active αβ2 holoenzyme can be produced and this is 
able to recruit the α’-subunit in a stable chimeric αα’β2 holoenzyme. 
Active 
Active Inactive 
Inactive 
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We also propose that binding of α-subunits to β-dimers is purely non-cooperative. 
The absence of any binding synergism could be inferred from the fact that no major struc-
tural rearrangement can be noticed in free and CK2α-bound β-dimer. 
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2.3 Conclusions 
With the final aim to study the possible structural role of the C-terminus of CK2α, 
which is usually deleted for crystallization purpose being easily degraded during the 
purification process, but it plays an active role during the cell cycle, we produced and 
crystallized a stable full-length CK2α phosphomimetic mutant (CK2αpm) and a tetrameric 
holoenzyme with the same catalytic subunit. Furthermore we produced, crystallized and 
solved the 3D structure of other two tetrameric holoenzymes, one with the wild-type full-
length CK2α (CK2αwt), and one with the deleted form of CK2α (CK2αdel).  
The purified CK2αpm was submitted to extensive crystallization trials but it was 
successfully crystallized only in the crystallization conditions known for the deleted form 
of the protein, with the same space group and with the same crystal packing. In addition, 
no extra electron density was visible for the last 59 residues, like in the case of the 
structure of the previously published deleted form. 
Regarding the full-length tetrameric holoenzymes, they were submitted to extensive 
crystallization trials and we optimized a new, never published, condition for the 
crystallization. Unfortunately, again it was not possible to visualize the electron density of 
the C-terminal tail because in the structures of the full-length holoenzymes the C-
terminus appears to be flexible and disorder. The main difference between the structures 
of the holoenzymes with the full-length CKα (CK2αpm and CK2αwt) and with the deleted 
form of CK2α (CK2αdel) is the space group: P21 for the full-length and C2 for the deleted 
CK2 holoenzyme. The crystal packing is very similar and the only difference has to be 
ascribed to the extra space required for the C-terminal tail. Our new tetrameric 
holoenzymes structures differ significantly with the previously published CK2 
holoenzyme structures. In particular the latter appears to be an asymmetric complex while 
our structure confutes this conformation with a more stable and symmetric holoenzyme, 
which is more in accordance with the functional and biochemical data present in 
literature. 
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3. CK2 holoenzymes: CK2α’2β2 and CK2αα’β2 
3.1 Methods 
3.1.1 Overview 
After the crystallization of the CK2 holoenzyme with the CK2α subunits, we 
focused the attention to the paralog isoform of the catalytic enzyme CK2α’. The paralog 
isoform of the catalytic subunit CK2α’, present in humans and higher animals, is very 
similar in sequence to the CK2α up to position 330, while the C-terminal segments differ 
completely in length and sequence. The thermostabilization of CK2α’ by the interaction 
with CK2β is much less than in the case of the CK2α and this, in accordance with other 
evidences, means that the affinity between CK2α' and CK2β is significantly lower than 
that between CK2α and CK2β (Olsen et al., 2006). The knowledge on CK2α’ is much 
lower than the paralog isoform CK2α; the main reasons are the reported solubility 
problems that occur after the expression in hosts cells like E. coli or insect cells. This 
problem was overcome with the genetic truncation of the C-terminal segment from 
Gln334 upwards (Nakaniwa et al., 2009) or by the single point mutation of the full-length 
protein where the Cys336 is mutated in Ser (Bischoff et al., 2011). We worked with the 
full-length mouse CK2α’ conjugated with the GST tag which may increase expression 
and solubility of the recombinant fusion protein and is useful for the first step of affinity 
chromatography. After the sequencing of the fragment encoding for the mouse CK2α’ we 
found that 14 amino acids coming from the MCS (Multiple Cloning Site) were present at 
the N-terminal tail of the protein, after the region encoding for the GST tag. At the 
beginning we decided to work with this long-form of the protein and try the level of 
expression and eventually the crystallization. After the difficulty in obtaining good 
diffracting crystals we decided to eliminate the 14 amino acids of the MCS at N-terminal 
tail firstly re-cloning the entire CK2α’ in a new vector without the GST tag and secondly 
by inserting a new cleavage site exactly after the 14 amino acids. In the end we tried to 
purify and crystallize the CK2α’2β2 starting from three different clones:  
1) GST-CK2α’2
long
 with the 14-amino acids tail at the N-terminal; 
2) CK2α’2
wt
 without the 14-amino acids tail and without the GST tag; 
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3) GST-CK2α’2
del
 without the 14-amino acids tail at the N-terminal and starting 
from amino acid 3 of the wt sequence. 
 
CK2α’_long  GST-trombine cleavage site-MATTHMDIGSGFPGIPGPAAGSRARVYAEVNSLRSREYWDYEAHVPSWGN 50 
CK2α’_MOUSE                            --------------MPGPAAGSRARVYAEVNSLRSREYWDYEAHVPSWGN 36 
CK2α’_HUMAN                            --------------MPGPAAGSRARVYAEVNSLRSREYWDYEAHVPSWGN 36 
                                                     :*********************************** 
 
CK2α’_long                             QDDYQLVRKLGRGKYSEVFEAINITNNERVVVKILKPVKKKKIKREVKIL 100 
CK2α’_MOUSE                            QDDYQLVRKLGRGKYSEVFEAINITNNERVVVKILKPVKKKKIKREVKIL 86 
CK2α’_HUMAN                            QDDYQLVRKLGRGKYSEVFEAINITNNERVVVKILKPVKKKKIKREVKIL 86 
                                       ************************************************** 
 
CK2α’_long                             ENLRGGTNIIKLIDTVKDPVSKTPALVFEYINNTDFKQLYQILTDFDIRF 150 
CK2α’_MOUSE                            ENLRGGTNIIKLIDTVKDPVSKTPALVFEYINNTDFKQLYQILTDFDIRF 136 
CK2α’_HUMAN                            ENLRGGTNIIKLIDTVKDPVSKTPALVFEYINNTDFKQLYQILTDFDIRF 136 
                                       ************************************************** 
 
CK2α’_long                             YMYELLKALDYCHSKGIMHRDVKPHNVMIDHQQKKLRLIDWGLAEFYHPA 200 
CK2α’_MOUSE                            YMYELLKALDYCHSKGIMHRDVKPHNVMIDHQQKKLRLIDWGLAEFYHPA 186 
CK2α’_HUMAN                            YMYELLKALDYCHSKGIMHRDVKPHNVMIDHQQKKLRLIDWGLAEFYHPA 186 
                                       ************************************************** 
 
CK2α’_long                             QEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHG 250 
CK2α’_MOUSE                            QEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHG 236 
CK2α’_HUMAN                            QEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRREPFFHG 236 
                                       *******************************************:****** 
 
CK2α’_long                             QDNYDQLVRIAKVLGTDELYGYLKKYHIDLDPHFNDILGQHSRKRWENFI 300 
CK2α’_MOUSE                            QDNYDQLVRIAKVLGTDELYGYLKKYHIDLDPHFNDILGQHSRKRWENFI 286 
CK2α’_HUMAN                            QDNYDQLVRIAKVLGTEELYGYLKKYHIDLDPHFNDILGQHSRKRWENFI 286 
                                       ****************:********************************* 
 
CK2α’_long                             HSENRHLVSPEALDLLDKLLRYDHQQRLTAKEAMEHPYFYPVVKEQSQPC 350 
CK2α’_MOUSE                            HSENRHLVSPEALDLLDKLLRYDHQQRLTAKEAMEHPYFYPVVKEQSQPC 336 
CK2α’_HUMAN                            HSENRHLVSPEALDLLDKLLRYDHQQRLTAKEAMEHPYFYPVVKEQSQPC 336 
                                       ************************************************** 
 
CK2α’_long                             AENTVLSSGLTAAR 364 
CK2α’_MOUSE                            AENTVLSSGLTAAR 350 
CK2α’_HUMAN                            ADNAVLSSGLTAAR 350 
                                       *:*:********** 
Figure 3.1 Sequence alignment of the mouse CK2α’long (CK2α’_long) form in comparison with 
the wild type mouse CK2α’(CK2α’_MOUSE) and with the human CK2α’ (CK2α’_HUMAN). 
 
Due to the difficulty on obtaining good diffracting crystals with all of the three 
CK2α’ variants, we tried to obtain a chimeric holoenzyme (found also in testis and brain 
physiologically) composed of the regulatory β2-dimer and of both the two catalytic 
subunits CK2α and CK2α'del. The crystallization of the homogenous CK2α’2β2 
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holoenzyme had a limit on the dimension reached by the crystal probably due to the 
unfavourable crystal packing within the crystal. In order to favor the crystallographic 
contacts we added a subunit more prone to the crystallization like the CK2αpm into the 
holoenzyme, purifying the chimeric holoenzyme CK2αpmα’delβ2. In order to purify the 
chimeric tetramer we firstly isolated the trimeric form CK2αpmβ2 during the purification 
of the holoenzyme CK2αpm2β2, and then we added free CK2α'
del
 previously purified (or 
expressed).  
 
3.1.2 Cloning 
1) CK2α’2
wtβ2 
To eliminate the 14 amino acids at the N-terminal tail, we decided to re-clone the 
entire fragment of CK2α' in a new vector, without the GST tag for the purification. The 
nucleotide sequence of CK2α' was amplified by PCR starting from the plasmid using two 
primers (in the box below) in order to insert a NdeI restriction site at the N-terminus and a 
HindIII restriction site at the C-terminus.  
 
Table 3.1 Primers for the PCR amplification of the mouse CK2α’wt 
Primers base Tm (°C) 
5' TACATATGCCCGGCCCGGCC 3' 20 66.5 
5' TTAAGCTTTCATCGTCGTGCTGCGGTGA 3' 28 61.6 
 
MIX: 2.5 μl reaction buffer, 2 μl of plasmid containing the sequence of CK2α'long, 
4.5 μl of each primers (4.5 pmol), 0.5 μl of dNTPs, 11.0 μl of H2O, 0.5 μl of DNA 
polimerase Genespin (2.5 U/μl). The amplified sequence was separated from the plasmid 
by extraction from agarose gel using PureLink Quick Gel Extraction Kit (Invitrogen).  
 
The PCR product was firstly phosphorylated using T4 Polynucleotide Kinase (New 
England BioLabs) and inserted into the pBluescript II SK (+/−) storage phagemid 
(Agilent Technologies) previously digested to create blunt ends by EcoRV restriction 
enzyme; this intermediate passage was fundamental for a successful digestion with NdeI 
and HindIII. After the digestion with restriction enzymes, the fragment with sticky ends 
was inserted in a linearized pET-20b vector (Novagen) digested with the same enzymes. 
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2) GST-CK2α’2
delβ2 
Due to the difficulty on expressing the protein without the GST tag in E. coli, we 
decided to insert a new restriction site for Prescission protease after the 14 amino acids 
and exactly before the sequence for CK2α'. To insert the new restriction site we used 
QuickChange Site-Directed Mutagenesis kit (Stratagene) and PfuTurbo DNA 
polymerase with the two primers in the box below: 
 
Table 3.2 Primers for the insertion of a new cleavage site for Prescission protease 
Primers base Tm (°C) 
5' CTGGAAGTTCTGTTCCAGGGCCCGGCCGCGGGCAGTCG 38 86.4 
3' GCCTAGGCTTAAGGGCCCCTAGGGGGACCTTCAAGACAAGGT 42 84.1 
 
MIX: 2.5 μl reaction buffer, 2 μl of plasmid containing the sequence of CK2α'long, 
4.5 μl of each primers (4.5 pmol), 0.5 μl of dNTPs, 11.0 μl of H2O, 0.5 μl of PfuTurbo 
DNA polimerase (2.5 U/μl). After 16 PCR cycles we add 1 μl of Dpn I restriction enzyme 
(10 U/μl) for the digestion of non-mutated DNA. 
 
3.1.3 Protein expression 
E. coli BL21(DE3) cells, harbouring the plasmid pT7-CK2β, pET-20b-CK2α’ (wt) 
and pGEX-CK2α’ (long and del) were grown overnight (ON) at 37 °C in LB medium (10 
g/l tryptone, 5 g/l yeast extract, and 10 g/l NaCl) supplemented with 50 μg/ml ampicillin. 
LB medium was inoculated with this ON culture (ratio 1:10) and grown at 37 °C, in a 
suitable shaker. Protein expression was induced at an OD600 of 0.6 by adding 1 mM IPTG 
and prolonged for 4-5 h at 30 °C under vigorous shaking. Bacteria were harvested by 
centrifugation at 5000 g for 30’. 
 
3.1.4 Protein purification 
Bacteria were suspended in buffer A [25 mM Tris-HCl (pH 8), 500 mM NaCl, 0.4 
mM (tris(2-carboxyethyl)phosphine) (TCEP)] supplemented with protease inhibitors 
EDTA free (Roche) mixed together to allow the formation of the tetrameric complex and 
lysed with a French press (Thermo Spectronic) at high pressure. 
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The lysate was centrifuged to remove cell debris at 27000 g for 30’ and filtered with 
0.22 μm syringe filter. The sample is loaded onto an affinity resin Glutathione Sepharose 
Fast Flow (GE Healthcare) in batch and equilibrated with buffer A. After extensive 
washing with buffer A we added to the resin the protease (Trombine or PreScission), 
which recognises the cleavage site at the beginning of the CK2α’ sequence, and incubated 
with the resin over night at 4 °C. After the cleavage the CK2α’ is eluted from the resin 
simply by washing with buffer A, while the GST is still bounded to the glutathione 
present on the resin. Fractions containing the CK2α’2β2 were pooled and further purified 
by size exclusion chromatography using a Superdex 200 prep-grade 26/60 column or a 
Superdex 200 10/300 (GE Healthcare) equilibrated with buffer B [25 mM Tris-HCl (pH 
8.5), 500 mM NaCl, and 0.2 mM TCEP]. 
For the chimeric holoenzyme we mixed the purified GST-CK2α’del (or its lysate) to 
the trimer CK2αpmβ2 and the first purification step was composed of an affinity 
chromatography using resin Glutathione Sepharose Fast Flow (GE Healthcare) in batch 
with buffer A; this purification step was fundamental to separate the CK2 tetramer which 
had incorporate a GST-CK2α’del with respect to the small portion of homogenous 
CK2αpm2β2. The second purification step was composed of a gel filtration 
chromatography with a Superdex 200 10/300 GL column with buffer B. The fastest 
method to obtain pure GST-CK2α’del is to purify the protein via an affinity column 
performed on a Äkta FPLC chromatographic system (GE Healthcare) using a HiTrap 
Heparin HP 5ml (GE Healthcare) equilibrated with buffer C [25 mM Tris-HCl (pH 8), 
300 mM NaCl, and 0.4 mM TCEP]. 
 
3.1.5 Protein crystallization 
Crystallization trials using commercial kits (Qiagen, Molecular Dimensions and 
Hampton Research) based on sparse matrix, grid screen, and/or ionic sampling, were 
performed by vapour diffusion (with the sitting drop method) techniques, using the Oryx8 
automatic system (Douglas Instrument). CK2α’2β2 was concentrated to 8 mg/ml for 
crystallization purposes. Crystals for the CK2α'2
longβ2 were grown at 20 °C with the vapor 
diffusion technique, using the following precipitant solution: 10% w/v PEG 4000, 20% 
v/v glycerol, 0.03 M of a mix composed of halogens, etilenglycol or monosaccharides and 
0.1 M buffer (Bicine, HEPES, MES), pH 8.5, 7.5, 6.5. Crystals for the CK2α'2
delβ2 grown 
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at 4 °C, using the following precipitant solution: PEG 400 25%, 0.1 M Tris pH 8.5, 150 
mM sodium citrate.  
CK2αpmα’delβ2 was concentrated to 8 mg/ml for crystallization purposes We 
obtained nice hexagonal crystal with the CK2αpmα'delβ2 grown at 20 °C, using the 
following precipitant solution: 0.24 M sodium malonate pH 7 and PEG 3350, 22%. 
3.1.6 Data collection 
We collected some images at the European Synchrotron Radiation Facility beamline 
ID23-2 gemini (ESRF Grenoble, France) and at the ELETTRA-Synchrotron beamline 
XDR1, (Trieste, Italy). 
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3.2 Results  
3.2.1 GST-CK2α’2longβ2 
3.2.1.1 Protein Expression and Purification 
We expressed both the GST-CK2α’long and the CK2β in E. coli BL21(DE3) in a 
ratio 1:2.5 of volume culture; even if the volume of the culture for the GST-CK2α’long is 
less than a half of the volume for the CK2β, we would have an excess of the first subunit 
due to a high expression level of the protein with the GST tag. To permit the formation of 
a stable GST-CK2α’2
longβ2 complex we lysated together the two bacterial pellets 
containing the two subunits and after the centrifugation and filtration we loaded the 
sample in an Glutathione Sepharose Fast Flow resin (GE Healthcare) in batch for the first 
affinity purification step. This step of purification uses the affinity between the fusion tag 
GST protein and the glutathione which the resin is functionalized with: only the protein 
with the GST tag would be able to bind to the resin while the bacterial lysate would elute 
from the column with the flow-through fraction. We worked with an excess of GST-
CK2α’long to avoid the formation of a double population of tetramers and trimers, like in 
the purification of the CK2α2β2 holoenzyme, which are difficult to separate and require 
more purification steps. 
We performed several washing cycles with buffer A [25 mM Tris-HCl (pH 8), 500 
mM NaCl, 0.4 mM TCEP] for eliminate the aspecific bindings. We didn’t use the 
standard protocol of purification which required the elution of the protein of interest from 
the column with a 5 mM glutathione solution and a subsequent cleavage the specific 
protease of the GST tag in solution. We rather preferred to add the Trombin protease 
directly in the column and left it incubate with the GST-CK2α’2
longβ2 over night at 4 °C; 
we decided to do this modification of the protocol to reduce the purification steps which 
may prompt to a degradation and loss of protein material due to the fact that the CK2α’ is 
reported to be very instable after the expression.  
After overnight incubation we eluted the protein form the column and the fraction 
was loaded in a coomassie‐stained SDS–PAGE (Figure 3.2). After the incubation with the 
protease a huge amount of protein precipitated within the resin (Lane 6) and only a small 
part of the CK2α’2
longβ2 remained soluble and could be eluted from the column (Lanes 7 
and 8). By the way the SDS-PAGE confirmed that the complex between CK2α’long and 
CK2β2 was formed. The purity of the sample could be good enough but we performed a 
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size exclusion chromatography to recruit information about the aggregation state of the 
protein and compare the elution volume with the other purified holoenzymes. The size 
exclusion chromatography was performed also to put the protein of interest in the buffer 
solution B [25 mM Tris-HCl (pH 8.5), 500 mM NaCl, 0.2 mM TCEP]. 
 
 
Figure 3.2 Coomassie‐stained SDS–PAGE of CK2α’2
longβ2 purification. Lanes 1 corresponds to 
the IPTG induced cells of CK2α’2
long. Lane 2 corresponds to the IPTG induced cells of CK2β. 
Lane 3 empty. Lane 4 soluble portion of bacterial lysate. Lane 5 insoluble fraction of bacterial 
lysate. Lane 6 resin after the cleavage. Lane 7 and 8 elution of the protein after the cleavage. 
Lane 9 low molecular weight protein markers. 
 
 
Figure 3.3 Elution profile of CK2α’2
longβ2 from size exclusion chromatography with a Superdex 
200 prep-grade 26/60 column (GE Healthcare) equilibrated with buffer B [25 mM Tris-HCl (pH 
8.5), 500 mM NaCl, and 0.2 mM TCEP]. 
 
The elution volume of the CK2α’2
longβ2 is comparable to the tetrameric form of the 
full-length CK2 holoenzyme. In this case we didn’t have a double population of 
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holoenzymes because we worked with an excess of CK2α’long. The sample was 
concentrated by ultrafiltration to a concentration of 8 mg/ml in a final volume of 160 μl 
with a final yield of 1.2 mg for 3.5 L of culture (0.3 mg per liter). 
 
3.2.1.2 Protein Crystallization 
Even with a low final yield of protein we were able to perform some 
crystallographic trials; we started from crystallization trials using commercial kits based 
on sparse matrix with the Oryx8 automatic system (Douglas Instrument). From the 
crystallization screenings that we tried, only the last kit, Morpheus (Molecular 
Dimension), gave several hits in the 96-wells plate, all containing very small and very 
thin microcrystals. All of the precipitant conditions which gave crystals had a similar 
precipitant composition made by 10% w/v PEG 4000, 20% v/v glycerol, 0.03 M of a mix 
composed by halogens, etilenglycol or monosaccharides and 0.1 M buffer (Bicine, 
HEPES, MES), pH 8.5, 7.5, 6.5. With the last aliquot of protein we tried to optimize the 
precipitant conditions, making some drops by hand; unfortunately the crystals grew only 
with the robot. However we were able to collect a data set at 8 Å for the CK2α’2
longβ2 
merging diffraction images coming from three different microcrystals; the radiation 
damage was very high for these crystals and after a small period of exposure the 
diffraction became null. 
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Figure 3.4 Detail of the diffraction image collected at the European Synchrotron Radiation 
Facility beamline ID23-2 gemini (ESRF Grenoble, France); the external spots correspond to a 
maximum resolution of 8 Å. 
 
The quality of the diffraction was good (Figure 3.4) but the intensity of the few 
spots was very low and it was not possible to elaborate the data. 
We obtained other crystals with the microseeding technique, but the limit was 
always the small dimension and the difficulty to manipulate the crystals. The difficulty on 
obtaining big diffracting crystals could be due to the high flexibility of some elements of 
the protein: we than decided to eliminate the 14 amino acids at the N-terminal tail of the 
CK2α’long. 
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3.2.2 CK2α’2wtβ2 
3.2.2.1 Cloning 
The first approach to eliminate the 14 amino acids at the N-terminal tail of the 
protein was to re-clone the entire sequence of mouse CK2α’ (CK2α’2
wt
) in a new 
expression vector. To do this we amplified the sequence of the CK2α’2
wtβ from the vector 
pGEX-CK2α’long with the primers listed in Table 3.1, which also insert a new restriction 
sites for the following insertion in the new expression vector. After the PCR we loaded 
the PCR product in a agarose gel with SYBR Green Safe dye; the PCR product have a 
dimension of 1053 bp and it was visible as a strong band at the level of the 1 kb marker 
(Figure 3.5). 
 
 
Figure 3.5 Agarose gel electrophoresis of the PCR product stained with SYBR Green Safe dye. 
Lane 1 marker of molecular weight markers in kb. Lane 2 control, PCR without primers. Lane 3 
PCR product. 
 
We performed an extraction from the gel using a PureLink Quick Gel Extraction Kit 
(Invitrogen) to obtain a pure PCR product. To insert the PCR product of CK2α’2
wt
 in a 
new expression vector we had to digest it with the restriction enzymes NdeI at the N-
terminus and HindIII at the C-terminus. After the gel extraction we noticed that the 
efficiency of the digestion by the restriction enzymes was very low on this linearized 
fragment; to avoid this problem we added an intermediate step in the protocol, cloning the 
fragment CK2α’wt into the pBluescript II SK (+/−) storage phagemid (Agilent 
Technologies). We firstly phosphorylated the PCR product with T4 Polynucleotide Kinase 
(New England BioLabs) and then inserted in the linearized pBSK vector previously 
digested to create blunt ends by EcoRV restriction enzyme. The efficiency of digestion by 
the restriction enzymes on a long DNA fragment, instead of the linearized PCR product, 
highly increased and this was confirmed by the agarose gel of the digested pBSK vector: 
the digestion was performed with the NdeI and HindIII restriction enzymes which were 
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able to recognize the restriction sites and digest the vector realising a sticky ends 
CK2α’2
wt
 fragment ready for the further insertion in the final expression vector. 
 
 
Figure 3.6 Agarose gel electrophoresis of the digestion of pBSK vector containing the CK2α’2
wt
 
fragment stained with SYBR Green Safe dye. Lanes 1-6 and 8-12 digestion products (pBSK vector 
= 3.4 kb and CK2α’2
wt
 = 1053 pb). Lane 7 marker of molecular weight markers in kb. 
 
The CK2α’2
wt
 fragment was than extracted from the gel with the same procedure 
described before and inserted in the final expression vector: the pET-20b was previously 
linearized with the restriction enzymes NdeI and HindIII, purified and dephosphorylated 
as from protocol. The final product of the ligation was than amplified in competent E. coli 
cells and digested with the same restriction enzymes: the digested sample was then loaded 
into an agarose gel for select the clones which had incorporated the correct vector. All the 
selected clones contained the CK2α’2
wt
 fragment correctly inserted in the pET-20b vector 
and the sequence was confirmed by DNA sequencing. 
 
 
Figure 3.7 Agarose gel electrophoresis of the digestion of pET-20b vector containing the 
CK2α’2
wt
 fragment stained with SYBR Green Safe dye. Lanes 1-5 and 7-11 digestion products 
(pET-20b vector = 3.7 kb and CK2α’2
wt
 = 1053 pb). Lane 6 molecular weight markers in kb. 
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3.2.2.2 Protein Expression 
Once obtained the final clone with the sequence codifying for CK2α’2
wt
 we verified 
the expression level in a small culture volume of E. coli BL21(DE3). We set up two 
different culture of 100 ml volume each with different induction temperature, 30 °C for 5 
hours (flask 1) and 20 °C for 16 hours (flask 2), after the reaching the OD600 of 0.7. The 
culture was than lysed and centrifuged and the soluble and insoluble fractions were 
loaded in a Coomassie‐stained SDS–PAGE. 
 
 
Figure 3.8 Coomassie‐stained SDS–PAGE of CK2α’2
wt
 expression. Lanes 1 corresponds to non-
inducted flask 1. Lane 2 corresponds to the non-inducted flask 2. Lane 3 and 4 IPTG induced cell 
after 2 hours in flask 1 and 2 respectively. Lane 5 Soluble fraction of flask 1 expression. Lane 6 
Insoluble fraction of flask 1 expression. Lane 7 Soluble fraction of flask 2 expression. Lane 8 
Insoluble fraction of flask 2 expression. Lane 9 low molecular weight protein markers. 
 
The expression level of the protein was very low or pretty much null. The GST is 
fundamental for the correct expression of the protein as crucial is its localization at the N-
terminus: in this way the expression of the fusion protein starts from the GST which 
permits the solubilisation of the CK2α’. Without the GST the protein seems to be 
insoluble and the bacterial cells are not able to express it; this in accordance with the fact 
that after the cleavage of the GST tag with the protease Trombin, more than a half of 
CK2α’2
longβ2 precipitates in column and only a small amount of holoenzyme remains in 
solution. We than decided to leave the GST tag but to insert a new cleavage site precisely 
after the 14 amino acids fragment. 
CK2α’2
wt
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3.2.3 CK2α’2delβ2 
3.2.3.1 Cloning 
To eliminate the 14 amino acids at the N-terminus we inserted a sequence of 
recognition for the PreScission Protease exactly before the sequence of the mouse 
CK2α’. PreScission Protease is a genetically engineered fusion protein consisting of 
human rhinovirus 3C protease and GST. It can be used following affinity purification or 
while fusion proteins are bound to Glutathione Sepharose 4 Fast Flow. It specifically 
cleaves between the Gln and Gly residues of the recognition sequence of Leu Glu Val 
Leu Phe Gln | Gly Pro. We used the residues 3 and 4 of the wild type CK2α’ as 
residues recognized by the PreScission Protease and we inserted the previous 6 residues 
by PCR mutagenesis. After the PCR the situation inside the plasmid is as it follows: 
 
                                     Leu Glu Val Leu Phe Gln   Gly Pro Ala Ala Gly Ser     
                14 aa             5' CTG GAA GTT CTG TTC CAG | GGC CCG GCC GCG GGC AGT CG 3' 
5' G CCT AGG CTT AAG GGC CCC TAG GGG GAC CTT CAA GAC AAG GTC 3'    CK2α' sequence 
Figure 3.9 In red the nucleotide sequence of the primer complementary to the sequence of the 14 
amino acids of the MCS; in black the sequence inserted by the primer recognized by the 
Prescission protease which cut at the level of the marker (|) between Gln and Gly and in green the 
sequence of the CK2α'.  
 
Note that after the digestion with the protease the first amino acids are Gly Pro 
while in the wild type form are Met Pro Gly Pro: we deleted 2 amino acids in the 
mutagenesis and the protein starts with residue Gly3 (GST-CK2α’del). 
The sequence has been confirmed by DNA sequencing. 
 
3.2.3.2 Protein Expression and Purification 
We expressed both the GST-CK2α’del and the CK2β in E. coli BL21(DE3) in a ratio 
1:2.5 of volume culture. We lysated together the two bacterial pellets within buffer A [25 
mM Tris-HCl (pH 8), 500 mM NaCl, 0.4 mM TCEP], centrifuged and filtrated with 0.22 
μm filter. The purification protocol is the same used for the purification of the 
CK2α’2
longβ2 apart from the adding of the PreScission Protease instead of the Trombine 
Protease after the first affinity chromatography. We loaded the lysate in the glutathione 
sepharose resin and we washed the column with ten column volumes. We added the 
PreScission Protease and left it acts in the column overnight at 4 °C. We eluted the 
purified protein from the column and we loaded the fractions collected in a 
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Coomassie‐stained SDS–PAGE. The PreScission Protease is fused with a GST tag and it 
remained bounded in the column. 
 
 
 
Figure 3.10 Coomassie‐stained SDS–PAGE of after the affinity chromatography. Lane 1 low 
molecular weight protein markers. Lanes 2-9 fractions of the elution of the protein after the 
cleavage. 
 
The PreScission Protease recognized the cleavage site and the result is a 40 kDa 
protein CK2α’del confirmed by the presence of the bands below the of 45 kDa band of the 
molecular weight protein marker. Also the band corresponding to the CK2β was present; 
the intensity of the band is lower in comparison with the CK2α’del because we worked in 
an excess of CK2α’del in the expression volumes. We had an excess of free CK2α’del in the 
elution sample and the next step of purification by size exclusion chromatography was 
fundamental to separate the holoenzyme from the free unbound catalytic subunit. 
We pooled together the fractions containing the protein and, after a concentration by 
ultracentrifugation, we loaded the sample in a Superdex 200 10/300 (GE Healthcare) 
equilibrated with buffer B [25 mM Tris-HCl (pH 8.5), 500 mM NaCl, and 0.2 mM 
TCEP]. 
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Figure 3.11 Elution profile of CK2α’2
delβ2 from size exclusion chromatography with a Superdex 
200 10/300 column (GE Healthcare) equilibrated with buffer B [25 mM Tris-HCl (pH 8.5), 500 
mM NaCl, and 0.2 mM TCEP] 
 
The elution profile of the CK2α’2
delβ2 is composed of a major peak which 
corresponds to the holoenzyme form and a small peak after the major one, which 
corresponds to the excess of free CK2α’2
del
 present in the sample eluted from the affinity. 
The purity of the sample was confirmed by a Coomassie‐stained SDS–PAGE of the 
fractions of the main peak. 
 
 
Figure 3.12 Coomassie‐stained SDS–PAGE of after the size exclusion chromatography. Lanes 1-3 
fractions of main peak of the elution profile. 
 
The purity of the sample is very high and we proceeded with the concentration of 
the sample by ultracentrifugation; the holoenzyme has been concentrated to 12.8 mg/ml 
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and the fraction containing the CK2α’del in excess were pulled together and concentrated 
to 7 mg/ml. The final yield had been optimized in respect to the first purification of the 
GST- CK2α’2
long
 and the final yield for the holoenzyme with this clone of CK2α’del was 1 
mg for 1 L of culture. 
 
3.2.3.3 Protein Crystallization 
We performed some crystallographic trials, starting from commercial kits based on 
sparse matrix with the Oryx8 automatic system (Douglas Instrument). From the crystalli-
zation trials we obtained different forms of microcrystals and some of them were tested at 
the the ELETTRA-Synchrotron beamline XDR1, (Trieste, Italy). We tried also different 
temperatures and the best condition reached the 7 Å resolution. The precipitant solution 
was composed of di PEG 400 25%, 0.1 M Tris-HCl pH 8.5, 150 mM sodium citrate; crys-
tals were very difficult to reproduce and we took the photo (Figure 3.13) before the meas-
urement at the synchrotron. 
 
 
Figure 3.13 Crystals of CK2α’2
delβ2 in PEG 400 25%, 0.1 M Tris-HCl pH 8.5, 150 mM sodium 
citrate.  
 
One more time the main problem in the crystallization of an holoenzyme with 
CK2α’2
del
 was the dimension reached by the crystals. We were able to collect only a small 
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number of diffraction images before the radiation damage and the disruption of the 
crystal. The crystal packing is probably not very compact, the crystallographic contacts 
are not favorable and there is a high amount of water which all contribute to the low 
diffraction limit and to the difficulty on obtaining big crystals. 
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3.2.4 CK2αpmα'delβ2 
3.2.4.1 Protein Expression and Purification 
We expressed the GST-CK2α’del in E. coli BL21(DE3). The best way to purify the 
chimeric holoenzyme is to purify separately the GST-CK2α’del and the trimer CK2αpmβ2 
before the mixing. We lysated the bacterial pellet of GST-CK2α’del within buffer C [25 
mM Tris-HCl (pH 8), 300 mM NaCl, 0.2 mM TCEP], centrifuged and filtrated with 0.22 
μm filter. We purified the GST-CK2α’del with a single purification step with Äkta FPLC 
chromatographic system (GE Healthcare) using a HiTrap Heparin HP 5 ml column (GE 
Healthcare). The elution was performed with an increasing concentration of NaCl and the 
chromatogram obtained is very similar to the previously purified CK2αpm. 
 
 
Figure 3.14 Elution profile of affinity chromatography of GST-CK2α’del on column: HiTrap 
Heparin (GE Healthcare) equilibrated with buffer C [25 mM Tris-HCl (pH 8), 300 mM NaCl, 0.4 
mM TCEP]. Elution performed with increasing percentage of buffer D [25 mM Tris-HCl (pH 8), 1 
M NaCl, 0.4 mM TCEP]. 
 
We pooled the fraction of the main peak and we loaded the elute in a 
coomassie‐stained SDS–PAGE (Figure 3.15); the GST-CK2α’del has an overall molecular 
weight of 66 kDa (26 kDa of the GST and 40 kDa of the CK2α’del). 
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Figure 3.15 Coomassie‐stained SDS–PAGE after affinity chromatography. Lanes 2-5 correspond 
to fractions of the main peak of the chromatogram and lane 1 corresponds to low molecular 
weight protein markers in kDa. 
 
We mixed the purified the GST-CK2α’del with the trimer of CK2αβ2 isolated in the 
previous purification (Result 2.2.2.1). After a short incubation of 10 minutes in ice, we 
loaded the sample in a Glutathione Sepharose Fast Flow resin (GE Healthcare) in batch: 
only the tetramer which had incorporated the GST-CK2α’del would be able to bind to the 
column unlike the contingent contamination of full tetramer CK2
pm
. We added the 
PreScission Protease and left it acts in the column overnight at 4 °C. We eluted the 
purified protein from the column and we loaded the fractions collected in a Superdex 200 
10/300 (GE Healthcare) equilibrated with buffer B [25 mM Tris-HCl (pH 8.5), 500 mM 
NaCl, and 0.2 mM TCEP]. With this purification step we isolated the chimeric 
CK2αpmα'delβ2 from the excess of CK2α'
del
 (Figure 3.14). 
The shift of exclusion volume of the CK2αpmα'delβ2 in comparison with the isolated 
form of CK2αpmβ2 used for the complex formation, confirms what was hypothesized 
during the first purification of the CK2 holoenzyme (Result 2.2.2.3): the trimeric form of 
CK2αpmβ2 is stable in solution and is able to recruit the other catalytic subunit to form a 
complete tetrameric complex. The molecular weight of the CK2αpmα'delβ2 calculated is 
214 kDa the elution volume is very similar to the CK2αpm2β2 one which had a calculated 
molecular weight of 230 kDa. As anticipated before the overestimation of the molecular 
weight is due to the presence of a full-length α-subunit (CK2αpm). The fact that the 55 
amino acids C-terminal tail of the α-subunit is able to increase the hydrodynamic volume 
of the full-length protein is confirmed also by the comparison of the elution volume 
between CK2αpmα'delβ2 and CK2α'
del
2β2 (figure 3.17): the calculated molecular weight of 
the CK2αdel2β2 is 170 kDa with respect to the 230 kDa of the last CK2α
pmα'delβ2. The 
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difference of 60 kDa is due to the 41 amino acids more present in the CK2αpm in the 
chimeric holoenzyme. 
 
Figure 3.16 Elution profile of size exclusion chromatography with a Superdex 200 10/300 column 
(GE Healthcare). In blue the elution profile of the CK2αpmα'delβ2: the main peak is the complete 
chimeric tetramer and the small peak is the excess of free CK2α'del. In red the elution profile of the 
trimer CK2αpmβ2 used for the formation of the chimeric holoenzyme. In green the elution profile of 
the complete CK2αpm2β2 tetramer as confront. 
 
Figure 3.17 Elution profile of size exclusion chromatography with a Superdex 200 10/300 column 
(GE Healthcare). In blue the elution profile of the CK2αpmα'delβ2. In violet the elution profile of 
CK2α’del2β2. 
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We loaded the fractions of the main peak in a Coomassie‐stained SDS–PAGE to 
analyze the purity of the sample and the composition of the chimeric holoenzyme. 
 
 
Figure 3.18 Coomassie‐stained SDS–PAGE after size exclusion chromatography. Lanes 1-5 
correspond to fractions of the main peak of the chromatogram. 
 
From the SDS-PAGE we could confirm that the chimeric holoenzyme is composed 
of the α-subunits CK2α’del and CK2αpm, and by the regulatory β2-dimer. The purity level 
was good enough and we proceed with the concentration of the sample by 
ultracentrifugation. The CK2αpmα'delβ2 was concentrated to 8 mg/ml and compared with 
the CK2α'del2β2 in a coomassie-stained SDS-PAGE. 
 
 
Figure 3.19 Coomassie‐stained SDS–PAGE after the concentration. Lane 1 corresponds to low 
molecular weight protein markers in kDa. Lane 2 and 3 correspond to CK2αpmα'delβ2 and 
CK2α'del2β2 respectively. 
 
3.2.4.2 Protein Crystallization 
We performed some crystallographic trials, starting from commercial kits based on sparse 
matrix with the Oryx8 automatic system (Douglas Instrument). We obtained nice small 
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hexagonal crystals but too small for being measured at the synchrotron (Figure 3.20). 
Again the dimension of the crystal is the limiting point of the experiment, but an 
enlargement of the photo shows that the crystal has a regular hexagonal symmetry. This 
hexagonal form could be a good starting point for the future optimization of the 
precipitant condition. 
 
 
Figure 3.20 Crystals of CK2αpmα'delβ2 grown in 0.24 M sodium malonate (pH 7) and PEG 3350 
22%. 
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3.3 Conclusions 
With the final purpose to develop a protocol for the production of the holoenzyme 
with the mouse CK2α’ subunit and the physiological chimeric holoenzyme composed of 
CK2α and CK2α’, we started with the full-length CK2α’ conjugated with the GST-tag 
which may increase the expression and solubility of the recombinant fusion protein. We 
were able to purify and crystallize the first form of CK2 holoenzyme with the α’ subunit 
which had a tail of 14 amino acids coming from the MCS, the multiple cloning site, 
(CK2α’long2β2). Due to the low resolution reached with this isoform (8 Å), we considered 
eliminate the MCS because it could be flexible and unstructured in solution 
compromising the growth of big ordered crystals. Therefore we reclone the wt CK2α’ 
(without the MCS, CK2α’wt) in a new expression vector without the fusion tag. In this 
case we were not able to purify the protein. We then proceeded with the cloning of a new 
form of CK2α’ (CK2α’del) which was expressed with the GST fusion tag and which had a 
cleavage site precisely after the MCS. After the cleavage, the final product is a soluble 
form of CK2α’ without the first two N-terminal amino acids. We were able to crystallize 
the latter form in a new crystallization condition, but the resolution achieved was only a 
little better than the first attempt (7 Å), but not enough to solve the structure. 
Due to the difficulty on obtaining good diffracting crystals with all of the three 
CK2α’ variants, we purified and crystallized a chimeric physiological holoenzyme 
composed of the regulatory β2-dimer and by both the two catalytic subunits CK2α and 
CK2α'del (CK2αpmα’delβ2). The crystallization of the homogenous CK2α’2β2 holoenzyme 
had a limit on the dimension reached by the crystal probably due to the unfavourable 
crystal packing within the crystal. In order to favor the crystallographic contacts we added 
a subunit more prone to the crystallization like the CK2αpm into the holoenzyme. We 
established a new protocol of purification starting from the isolation of the trimeric form 
CK2αpmβ2, followed by the adding of free CK2α'
del
 previously purified (or expressed). We 
obtained small hexagonal crystals, too small for the diffraction analysis, but very 
promising for future optimization. 
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4. CK2α336 inhibition 
4.1 Methods 
4.1.1 Overview 
A part of my PhD project focused on the interaction between CK2 and small ligand 
which can compete with the ATP for the binding to the kinase. In collaboration with the 
laboratory of Professor Pinna, we studied the interaction between the CK2α336 (deleted at 
residue Ser336) and a potent and selective Type I ATP-competitive inhibitor, called K164. 
The inhibitor exhibits all the features which make a small ligand attractive for inhibition 
studies: all the structural characteristics like hydrophobicity and possibility to establish 
electrostatic interactions are satisfied like the high cell permeability which makes the 
molecule a useful biochemical tool also with pharmacological potentials, due to the fact 
also that is selective for two different kinases: CK2 and Pim1. Both of the kinases are 
involved in cancer development and have been considered as potential pharmacological 
target, and so having a potent inhibitor, cell permeable and selective for both of the 
kinases is surely of high interest. 
 
4.1.2 Protein expression and purification 
Recombinant human CK2α336 was purified, after expression in bacterial strain E. 
coli BL21(DE3), with three chromatographic step. The first step was an affinity 
cromatography performed on an Äkta FPLC chromatographic system (GE Healthcare) 
using a HiTrap Heparin HP 5ml (GE Healthcare) equilibrated with buffer A [25 mM Tris-
HCl (pH 8), 0.4 M NaCl and 1 mM dithiothreitol (DTT) as a reducing agent]. The protein 
was eluted with a NaCl gradient (mM Tris-HCl (pH 8), 1 M NaCl, 1 mM DTT, buffer B) 
and the most pure fractions were pooled, dialysed into a buffer C [25 mM Tris (pH 8.5), 
0.1 M NaCl, 1 mM DTT], and loaded onto an anionic exchange column (MonoQ, GE 
Healthcare) equilibrated with the same buffer. CK2α336 was eluted in a single peak after a 
NaCl gradient. The third purification step was a gel filtration chromatography using a 
Superdex 75 10/300 column (GE Healthcare) equilibrated with buffer D [25 mM Tris-
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HCl (pH 8.5), 500 mM NaCl, and 1 mM DTT]. The purified protein was then 
concentrated to 10 mg/ml for crystallization purposes. 
 
4.1.3 Protein crystallization  
We solved the crystal structure of the complex obtained by soaking the inhibitor (5 
mM) on a crystal growth by vapour diffusion (with the sitting drop method) techniques, 
made by hand with a CK2α336 concentrated to 10 mg/ml incubated for 10 minutes with an 
equal volume of milliq water with 1.5% DMSO. Crystals were grown at 20 °C, using the 
following precipitant solution: 0.2 M lithium sulfate, Tris-HCl pH 8.5, 32% w/v PEG 
4000. 
 
 
4.1.4 Data Collection, structure determination, and refinement  
The data set was collected at the ELETTRA-Synchrotron beamline XDR1, (Trieste, 
Italy). Data set was measured at 100 K using the precipitant solution, including 10% 
glycerol as cryo-protectant, at the bromine absorption edge, 0.91 Å wavelength, to detect 
the anamalous signal and better define the position of the 4 bromines present in the 
inhibitor. CK2α336 crystals belonged to space group P21 with unit cell parameters reported 
in Table 3.1. Diffraction data were processed with XDS and reduced and merged with 
SCALA included in the CCP4 suite. The structure was solved by molecular replacement 
using the structure of the CK2αdel 3BQC. The model was then refined alternating several 
cycles of automatic refinement with REFMAC (CCP4) and manual model building with 
Coot. 
 
4. CK2α336 inhibition 
101 
4.2 Results 
4.2.1 Protein Expression and Purification 
The purification protocol of CK2α336 is the same used for the CK2αpm with an 
additional intermediate chromatographic step between the affinity chromatography and 
the size exclusion chromatography: the anion exchange chromatography is fundamental 
to obtain a pure final protein. 
 
 
Figure 4.1 Elution profile of affinity chromatography of CK2α336 on column: HiTrap Heparin 
(GE Healthcare) equilibrated with buffer A [25 mM Tris-HCl (pH 8), 350 mM NaCl, 1 mM DTT]. 
Elution performed with increasing percentage of buffer B [25 mM Tris-HCl (pH 8), 1 M NaCl, 1 
mM DTT]. 
 
After the affinity with the heparin column we dialyzed the protein into the buffer C 
[25 mM Tris (pH 8.5), 0.1 M NaCl, 1 mM DTT]: in this step a great amount of protein 
underwent to precipitation. We loaded the protein into the MonoQ column and we 
performed the elution with a NaCl gradient.  
 
0
10
20
30
40
50
60
70
80
90
100
0
500
1000
1500
2000
2500
0 20 40 60 80 100
HiTrap Heparin 
 
B
 (
%
) 
m
A
U
 
ml 
 mAU
 %B
4.2. Results  
102 
 
Figure 4.2 Elution profile of affinity chromatography of CK2α336 on column: MonoQ (GE 
Healthcare) equilibrated with buffer C [25 mM Tris-HCl (pH 8.5), 0.1 mM NaCl, 1 mM DTT]. 
Elution performed with increasing percentage of buffer C
a
 [25 mM Tris-HCl (pH 8.5), 1 M NaCl, 
1 mM DTT]. 
 
After the anion exchange chromatography we pulled together the fractions and we 
performed the third purification step represented by a size exclusion chromatography 
using a Superdex 75 10/300 (GE Healthcare) equilibrated with buffer D, the final buffer 
of the purification. 
 
 
Figure 4.3 Elution profile of size exclusion chromatography with a Superdex 75 10/300 column 
(GE Healthcare) equilibrated with buffer D [25 mM Tris-HCl (pH 8.5), 500 mM NaCl, and 1 mM 
DTT] 
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The elution profile of the size exclusion chromatography showed a single slightly-
tailed peak; we loaded the fractions of the main peak in a coomassie‐stained SDS–PAGE 
for evaluate the purity level of the sample after the size exclusion chromatography. 
 
 
Figure 4.4 Coomassie‐stained SDS–PAGEs after size esclusion chromatography. Lanes 1-9 
correspond to fractions of the main peak of the chromatogram. 
After the size exclusion chromatography the purity of the sample was high enough 
for the crystallization purpose. We collected all the fractions and the CK2α336 was 
concentrated to 10 mg/ml by ultrafiltration. 
 
4.2.2 Protein crystallization 
We knew that CK2α336 gives good diffracting crystal under an optimized precipitant 
solution with 0.1 M Tris-HCl (pH 8.5), 0.2 lithium sulphate and 32% w/v PEG 4000 in 
P21 space group. We optimized the condition to obtain crystal of the apo form of the 
protein and then we added the inhibitor by crystal soaking (co-precipitation did not work). 
To obtain big and good diffracting crystals we mixed the CK2α336 10 mg/ml with an equal 
volume of distilled water with DMSO 1.5-2 %; the supplement of a small amount of 
DMSO is fundamental for the crystal formation of the apo form of the protein. After an 
incubation of 10 minutes the protein was centrifuged for 10 minutes at 5000 g at 4 °C. 
The crystallization drop for the apo form was composed by 1 μl of CK2α336 5 mg/ml, 1 μl 
of the precipitant solution and equilibrated against 400 l of reservoir. All crystals grew in 
about one week. The inhibitor solution used for the soaking was composed by the 
precipitant solution plus K164 10 mM. We added to the crystal 1 μl of the inhibitor 
solution to achieve a final concentration of 5 mM. The crystals were cryoprotected by 
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adding 2 l of the inhibitor solution with ethylene glycol 10% to the drop before crystal 
freezing. 
 
Figure 4.5 Crystals of CK2α336 in 0.1 M Tris-HCl (pH 8.5), 0.2 lithium sulphate and 32% w/v 
PEG 4000. 
 
4.2.3 Structure determination 
The structure was solved by molecular replacement using the structure of the 
CK2αdel 3BQC. Statistics on data collections and refinement are reported in table 4.1. 
CK2α336 crystallized in the space group P21. The overall structure of the enzyme within 
the crystal packing is identical to the published CK2α336. The structure reached the 1.25 Å 
resolution which is the higher resolution ever published for CK2 α336 protein. 
Table 4.1 Data collection and refinement statistics 
Data collection statistics ELETTRA beamline XDR1, =0.91 Å 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
58.45 45.82 63.49 
90 111.1 90 
Total number of observations 471404 (22651) 
Total number of unique 86589 (4286) 
Resolution (Å) 45.82 (1.25) 
Rmerge (%) 0.061 (0.773) 
Rmeas (%) 0.075 (0.949) 
I/σ(I) 12.5 (1.9) 
Completeness (%) 99.8 (100.0) 
Multeplicity 5.4 (5.3) 
Refinement statistics 
Rwork (%) 0.13437 
Rfree (%) 0.17543 
The values in brackets are referred to the highest resolution shell. 
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4.2.4 CK2α336 structure in complex with the inhibitor K164 
The first inhibitor for CK2 described in 1984 was the inhibitor DRB (IC 50 is >10 
µM) (Figure 4.6); later it was described that removing the sugar ring and replacing the 
two chlorines with up to 4 bromines prompt to an increasing of the potency of the 
inhibitors: 4,5,6,7-tetrabromo-benzimidazole (TBI) and 4,5,6,7-tetrabromo-benzotriazole 
(TBB) both display IC50 /Ki values lower than 1 µM. Further TBI was modified on its 
imidazole ring giving a variety of derivatives listed in Figure 4.6, with an improved 
potency.  
 
Figure 4.6 Structure of selected ATP site-directed CK2 inhibitors polyhalogenated 
benzimidazoles. 
 
The most crucial binding interactions for TBB and TBI compounds are due to 
hydrophobic and van der Waals contributions, produced by the presence of the four apolar 
bulky bromine atoms which lead the inhibitor away from the aqueous phase towards the 
more apolar area of the CK2 active site. For the other derivatives, the preferred 
interaction is with the backbone of the hinge region: in particular, they establish two 
halogen bonds between bromine atoms and the carbonyls of Glu114 and Val116. It has 
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been shown that these compounds have two different orientations, one rotated about 60° 
around the axis perpendicular to the plane of the molecule with respect to the other 
(Figure 4.6).  
 
 
Figure 4.7 The two different orientations of the tetrabromobenzo derivatives in the active site of 
protein kinase CK2α. In orientation 1 inhibitors (DMAT, K32, K22, K66 and K68) interact with 
the hinge region via two bromines in position D and D’, while in orientation 2 (K44, K64 and 
K74) via bromines in position C’ and D’. Orientation 1 is preferred when there are no functional 
groups in positions A and A’, or if in position A there is a functional group capable of interacting 
with the positive area of the ATP binding site. Orientation 2 is preferred when position A’ carries 
a hydrophobic substituent. 
 
From the analysis of all the published structures it can be conclude that if there are 
no functional groups in positions A and A’, or if in position A there is a functional group 
capable of interacting with the positive area of the ATP binding site, the preferred 
conformation adopted by the inhibitors is the “conformation 1” (as in the case of DMAT, 
K32, K22, and K66 and K68 presented here), with Br5 and Br6 interacting with the hinge 
region. Instead, if position A’ carries a hydrophobic moiety (as in the case of K44, K64 
and K74), this group tends to orient itself towards the external part of the cleft and the 
whole orientation of the inhibitor is that indicated as “conformation 2”, with Br4 and Br5 
interacting with the hinge region (Sarno et al., 2011). 
The inhibitor K164 is a potent dual inhibitor, specific for Pin1 and CK2, designed 
from the structure of the DRB. The sugar ring is kept in the formula but instead of the two 
chloride atoms, we have four bromines atoms with a final tetrabromobenzo derivative 
(Figure 4.8). The inhibitor was found in an orientation similar to the orientation 2 (Figure 
4.7) showed above. The two bromines Br4 and Br5 point in the direction of the hinge 
region, towards the backbone of Val116 and Glu114 respectively. Like in K64 structure 
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the Br6 interacts with a conserved water molecule W2 and the Br7 makes an halogen 
bond with the side chain of Asp175. The Asp175 is shifted away from the canonical 
conformation towards the ligand but is still present the salt bridge with the Lys68 which is 
itself shifted towards the K164 molecule. This confirms that the presence of a bromine 
atom near the Asp175 leads a movement of the side chain. If compared with the other 
tetrabromobenzo derivatives, the K164 is shifted towards the N-terminal lobe of the 
protein and it goes less inside the cavity of CK2. This is probably due to the presence of 
the deoxyribose ring which is bulky and flexible and it doesn’t allow the inhibitor to fill 
deeply the active site. In fact, a certain degree of flexibility of the deoxyribose ring is 
confirmed by the poor quality of its electron density; the deoxyribose ring doesn’t 
contribute directly to the binding with CK2 but it can be important for the binding to the 
other kinase, Pim1. 
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Figure 4.8 (A) Structure of the inhibitor K164. (B) K164 bound to the ATP-binding site of 
CK2α336. Main polar interactions are indicated with black yellow dashed lines and water 
molecule is indicated by a small red sphere. (C) Comparison between different inhibitors: note 
how the binding conformation of K164 (in yellow) is similar to the K64 (in cyan) with respect to 
the K68 (in purple) and how the inhibitor K164 is shifted towards the external part of the cavity. 
(D) Electron density of the K164 in complex with the CK2α336: note the poor quality of the 
electron density of the deoxyribose ring with respect to the rest of the molecule. 
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4.3 Conclusions 
In order to study the interaction between the CK2α336 (deleted at residue Ser336) 
and a potent and selective Type I ATP-competitive inhibitor, called K164, we purified and 
crystallized CK2α336 in the apo form. To obtain a reproducible condition for the 
crystallization, we optimized the precipitant solution with the adding of a small 
percentage of DMSO. After the growth of these big crystals, we soaked the crystal with a 
solution containing the inhibitor. Then we collected the data and we solved the structure 
with the final resolution of 1.25 Å. 
Concluding we solved the first structure of the human CK2α336 in complex with a 
tetrabromobenzo derivative and we were able to reach the highest resolution for the CK2 
protein. The K164 interacts with the CK2α336 like it was described for the other 
tetrabromobenzo derivatives (Sarno et al., 2011) and the structure confirms the model 
proposed for the binding of this kind of ligands: if the molecule carries an hydrophobic 
moiety (like the deoxyribose ring), this part of the ligand is oriented towards the external 
part of the cavity and the inhibitor adopts conformation described as orientation 2 (Figure 
4.7). 
Being a dual inhibitor, this strucure is only the first half a more complex work: the 
structure in complex with the opther kinase would be crucial to understad the nature of 
the dual potency of the molecule and to put the basis for the design of more potent dual 
inhibitors for CK2 and Pim1 kinase. 
 
  
4.3. Conclusions  
110 
  
5. Bibliography 
111 
5. Bibliography 
 
Ahn, N. G. and Resing, K. A. (2001). Toward the phospho- proteome. Nat. 
Biotechnol. 19: 317-318 
 
Battistutta, R., Sarno, S., De Moliner, E., Marin, O., Issinger, O. G., Zanotti, G., 
Pinna, L. A. (2000). The crystal structure of the complex of Zea mays alpha subunit with 
a fragment of human beta subunit provides the clue to the architecture of protein kinase 
CK2 holoenzyme. Eur J Biochem 267: 5184-5190 
 
Battistutta, R. (2009). Protein kinase CK2 in health and disease: Structural bases of 
protein kinase CK2 inhibition. Cell Mol Life Sci. 66: 1868-1889 
 
Battistutta, R., Lolli, G. (2011). Structural and functional determinants of protein 
kinase CK2α: facts and open questions. Mol Cell Biochem. 356: 67-73 
 
Bischoff, N., Olsen, B., Raaf, J., Bretner, M., Issinger, O-G., Niefind, K. (2011). 
Structure of the Human Protein Kinase CK2 Catalytic Subunit CK2α' and Interaction 
Thermodynamics with the Regulatory Subunit CK2β. J. Mol. Biol. 407: 1-12 
 
Boldyreff, B., Meggio, F., Pinna, L. A., Issinger, O. G. (1993). Reconstitution of 
normal and hyperactivated forms of casein kinase-2 by variably mutated β-subunits. 
Biochemistry. 32: 12672-12677 
 
Bosc, D. G., Slominski, E., Sichler, C. and Litchfield, D. W. (1995). 
Phosphorylation of casein kinase II by p34cdc2. Identification of phosphorylation sites 
using phosphorylation site mutants in vitro. J. Biol. Chem. 270: 25872-25878 
 
Buchou, T., Vernet, M., Blond, O., Jensen, H. H., Pointu, H., Olsen, B. B., Cochet, 
C., Issinger, O. G., and Boldyreff, B. (2003). Disruption of the regulatory beta subunit of 
protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic 
lethality. Mol. Cell. Biol. 23: 908-915 
5. Bibliography  
112 
Burnett, G. and Kennedy, E. P. (1954). The enzymatic phosphorylation of proteins. 
J. Biol. Chem. 211: 969-980 
 
Canton, D.A., Zhang, C., Litchfield, D. W. (2001). Assembly of protein kinase 
CK2: investigation of complex formation between catalytic and regulatory subunits using 
a zinc-finger deficient mutant of CK2β. Biochem J. 358: 87-94 
 
Chantalat, L., Leroy, D., Filhol, O., Nueda, A., Benitez, M. J., Chambaz, E. M., 
Cochet, C., Dideberg, O. (1999). Crystal structure of the human protein kinase CK2 
regulatory subunit reveals its zinc finger-mediated dimerization. EMBO J. 18: 2930-2940 
 
Cohen, P. (2000). The regulation of protein function by multisite phosphorylation – 
a 25 year update. Trends Bio-chem. Sci. 25: 596-601 
 
Di Maira, G., Brustolon, F., Tosoni, K., Belli, S., Kramer, S. D., Pinna, L. A. and 
Ruzzene, M. (2008). Comparative analysis of CK2 expression and function in tumor cell 
lines displaying sensitivity vs. resistance to chemical induced apoptosis. Mol. Cell. 
Biochem. 316: 155-161 
 
  Emsley, P., Cowtan K. (2004). Coot: model-building tools for molecular graphics. 
Acta Crystallogr D Biol Crystallogr 60(12 1): 2126-2132 
 
  Evans, P. (2005). Scaling and assessment of data quality. Acta Crystallogr D Biol 
Crystallogr 62(1): 72-82 
 
Fabbro, D., Cowan-Jacob, S. W., Mobitz, H., Martiny-Baron, G. (2012). Targeting 
cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol 795: 1-34 
 
Glover, C. V. (1986). A filamentous form of Drosophila casein kinase II. J Biol 
Chem. 261: 14349-14354 
 
Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100: 57-70 
 
5. Bibliography 
113 
Hanks, S. K. and Hunter, T. (1995). Protein kinases 6. The eukaryotic protein kinase 
superfamily: 
kinase (catalytic) domain structure and classification. FASEB J. 9: 576-596 
 
Hemmings, B. A., Restuccia, D., Tonks, N. (2009). Targeting the Kinome II. Curr 
Opin Cell Biol 21: 135-139 
 
Hjerrild, M., Milne, D., Dumaz, N., Hay, T., Issinger, O. G. and Meek, D. (2001). 
Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by 
protein kinase CK2 in vitro and in cultured cells. Biochem. J. 355: 347-356 
 
Imming, P., Sinning, C., Meyer, A. (2006). Drugs, their targets and the nature and 
number of drug targets. Nat Rev Drug Discov 5: 821-834 
 
Kabsch, W. (2010) XDS. Acta Cryst. D66: 125-132 
 
Kapoor, M. and Lozano, G. (1998). Functional activation of p53 via 
phosphorylation following DNA damage by UV but not gamma radiation. Proc. Natl. 
Acad. Sci. USA 95: 2834-2837 
 
Kornev, A. P., Haste, N. M., Taylor, S. S. and Ten Eyck, L. F. (2006). Surface 
comparison of active and inactive protein kinases identifies a conserved activation 
mechanism. Proc. Natl Acad. Sci. USA 103(47): 17783 –17788 
 
Kornev, A. P., Taylor, S. S., Ten Eyck, L. F. (2008). A helix scaffold for the 
assembly of active protein kinases. Proc Natl Acad Sci USA. 105:14377-14382 
 
Krebs, E. G. (1998). An accidental biochemist. Annu. Rev. Biochem. 67: xii-xxxii 
 
Krissinel, E. and Henrick K. (2007). Inference of macromolecular assemblies from 
crystalline state. J Mol Biol 372(3): 774-97 
 
Laudet, B., Barette, C., Dulery, V., Renaudet, O., Dumy, P., Metz, A., Prudent, R., 
5. Bibliography  
114 
Deshiere, A., Dideberg, O., Filhol, O., Cochet, C. (2007). Structure-based design of 
small peptide inhibitors of protein kinase CK2 subunit interaction. Biochem J. 408: 
363-373 
 
Leroy, D., Schmid, N., Behr, J. P., Filhol, O., Pares, S., Garin, J., Bourgarit, J. J., 
Chambaz, E. M., Cochet, C. (1995). Direct identification of a polyamine binding domain 
on the regulatory subunit of the protein kinase casein kinase 2 by photoaffinity labeling. J 
Biol Chem. 270: 17400-17406 
 
Litchfield, D. W., Lozeman, F. J., Cicirelli, M. F., Harrylock, M., Ericsson, L. H., 
Piening, C. J. and Krebs, E. G. (1991). Phosphorylation of the beta subunit of casein 
kinase II in human A431 cells. Identification of the autophosphorylation site and a site 
phosphorylated by p34cdc2. J. Biol. Chem. 266(30): 20380-20389 
 
Litchfield, D. W. (2003). Protein kinase CK2: structure, regulation and role in 
cellular decisions of life and death. Biochem. J. 369: 1-15 
 
Lolli, G., Pinna, L. A., Battistutta, R. (2012). Structural determinants of protein 
kinase CK2 regulation by autoinhibitory polymerization. ACS Chem Biol 7(7): 1158-1163 
 
Lopez-Ramos, M., Prudent, R., Moucadel, V., Sautel, C. F., Barette, C., 
Lafanechere, L., Mouawad, L., Grierson, D., Schmidt, F., Florent, J. C., Filippakopoulos, 
P., Bullock, A. N., Knapp, S., Reiser, J. B., Cochet, C. (2010). New potent dual inhibitors 
of CK2 and Pim kinases: discovery and structural insights. Faseb J 24: 3171-3185 
 
Lorenz, P., Pepperkok, R., Ansorge, W. and Pyerin, W. (1993). Cell biological 
studies with monoclonal and polyclonal antibodies against human casein kinase II subunit 
beta demonstrate participation of the kinase in mitogenic signaling. J. Biol. Chem. 268: 
2733-2739 
 
Lorenz, P., Pepperkok, R. and Pyerin, W. (1994). Requirement of casein kinase 2 for 
entry into and progression through early phases of the cell cycle. Cell. Mol. Biol. Res. 40: 
519-527 
 
5. Bibliography 
115 
Lou, D. Y., Dominguez, I., Toselli, P., Landesman-Bollag, E., O’Brien, C. and 
Seldin, D. C. (2008). The alpha catalytic subunit of protein kinase CK2 is required for 
mouse embryonic development. Mol. Cell. Biol. 28: 131-139 
 
Manning, G., Whyte, D.B., Martinez, R., Hunter, T., Sudarsanam, S. (2002). The 
Protein Kinase Complement of the Human Genome. Science 298(5600): 1912-1934 
 
Manning, G., Plowman, G. D., Hunter, T., Sudarsanam, S. (2002 b). Evolution of 
protein kinase signaling from yeast to man. Trends Biochem. Sci. 27: 514-520 
 
Marchiori, F., Meggio, F., Marin, O., Borin, G., Calderan, A., Ruzza, P., Pinna, L.A. 
(1988). Synthetic peptide substrates for casein kinase 2. Assessment of minimum 
structural requirements for phosphorylation. Biochim Biophys Acta 971: 332-338 
 
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., 
Read R. J. (2007). Phaser crystallographic software. J Appl Crystallogr 40(4): 658-674 
 
McDonnell, M. A., Abedin, M.J., Melendez, M., Platikanova, T. N., Ecklund, J. R., 
Ahmed, K. and Kelekar, A. (2008). Phosphorylation of murine caspase-9 by the protein 
kinase casein kinase 2 regulates its cleavage by caspase-8. J. Biol. Chem. 283: 20149-
20158 
 
Meggio, F., Pinna, L. A. (2003). One-thousand-and-one substrates of protein kinase 
CK2? FASEB J. 17: 349-368 
 
Messenger, M. M., Saulnier, R. B., Gilchrist, A. D., Diamond, P., Gorbsky, G. J. and 
Litchfield, D. W. (2002). Interactions between protein kinase CK2 and Pin1. Evidence for 
phosphorylation-dependent interactions. J. Biol. Chem. 277: 23054-23064 
 
  Murshudov, G. N., Vagin, A. A., Dodson E. J. (1997). Refinement of 
macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol 
Crystallogr 53(3): 240-255 
 
5. Bibliography  
116 
 Nakaniwa, T., Kinoshita, T., Sekiguchi, Y., Tada, T., Nakanishi, K., Kitaura, Y., 
Suzuki, Y., Ohno, H., Hirasawa, A., Tsujimoto, G. (2009). Structure of human protein 
kinase CK2a2 with a potent indazolederivative inhibitor. Acta Crystallogr. Sect. F 65: 75-
79 
 
Nasmyth, K. (1996). Viewpoint: putting the cell cycle in order. Science 274: 1643-
1645 
 
Niefind, K., Battistutta, R.(2012) Structural bases of protein kinase CK2 function 
and inhibition.  
 
Niefind, K., Guerra, B., Pinna, L. A., Issinger, O. G., Schomburg, D. (1998). Crystal 
structure of the catalytic subunit of protein kinase CK2 from Zea mays at 2.1 Å 
resolution. EMBO J. 17: 2451-2462 
 
Niefind, K., Guerra, B., Ermakowa, I., Issinger, O. G. (2001). Crystal structure of 
human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO 
J. 20: 5320-5331 
 
Niefind, K., Raaf, J., Issinger, O.G. (2009). Protein kinase CK2 in health and 
disease: Protein kinase CK2: from structures to insights. Cell Mol Life Sci. 66: 1800-1816 
 
 Olsen, B. B., Boldyreff, B., Niefind, K. and Issinger, O. G. (2006). Purification 
and characterization of the CK2a'-based holoenzyme, and isozyme of CK2a: a 
comparative analysis. Protein Expression Purif. 47: 651–661 
 
Pagano, M. A., Sarno, S., Poletto, G., Cozza, G., Pinna, L. A., and Meggio, F. 
(2005). Autophosphorylation at the regulatory beta subunit reflects the supramolecular 
organization of protein kinase CK2. Mol. Cell. Biochem. 274: 23−29 
 
Papinutto, E., Ranchio, A., Lolli, G., Pinna, L. A., Battistutta, R. (2012). Structural 
and functional analysis of the flexible regions of the catalytic alpha-subunit of protein 
kinase CK2. J Struct Biol. 177: 382-391 
 
5. Bibliography 
117 
Pepperkok, R., Lorenz, P., Ansorge, W. and Pyerin, W. (1994). Casein kinase II is 
required for transition of G0/G1, early G1, and G1/S phases of the cell cycle. J. Biol. Chem. 
269: 6986-6991 
 
Pierre, F., Chua, P. C., O'Brien, S. E., Siddiqui-Jain, A., Bourbon, P., Haddach, M., 
Michaux, J., Nagasawa, J., Schwaebe, M. K., Stefan, E., Vialettes, A., Whitten, J. P, Chen, 
T. K., Darjania, L., Stansfield, R., Anderes, K., Bliesath, J., Drygin, D., Ho, C., Omori, 
M., Proffitt, C., Streiner, N., Trent, K., Rice, W. G., Ryckman, D. M. (2011). Discovery 
and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-
4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J 
Med Chem 54: 635-654 
 
Pinna, L. A., Meggio, F., Marchiori, F., Borin, G. (1984). Opposite and mutually 
incompatible structural requirements of type-2 casein kinase and cAMP-dependent 
protein kinase as visualized with synthetic peptide substrates. FEBS Lett. 171: 211-214 
 
Pinna, L. A. (1994). A historical view of protein kinase CK2. Cell. Mol. Biol. Res. 
40: 383-390 
 
Pinna, L. A. (2002). Protein kinase CK2: a challenge to canons. J Cell Sci. 115: 
3873-3878 
 
Poole, A., Poore, T., Bandhakavi, S., McCann, R. O., Hanna, D. E., Glover, C. V. 
(2005). A global view of CK2 function and regulation. Mol Cell Biochem. 274: 163-170 
 
Raaf, J., Brunstein, E., Issinger, O. G., Niefind, K. (2008). The interaction of CK2α 
and CK2β, the subunits of protein kinase CK2, requires CK2β in a preformed 
conformation and is enthalpically driven. Protein Sci. 17: 2180-2186 
 
Raaf, J., Brunstein, E., Issinger, O. G., Niefind, K. (2008b). The CK2α/CK2β 
interface of human protein kinase CK2 harbors a binding pocket for small molecules. 
Chem Biol. 15: 111-117 
 
Rodnight, R., Lavin, B. E. (1964). Phosvitin kinase from brain: activation by ions 
5. Bibliography  
118 
and subcellular distribution. Biochem. J. 93: 84-91 
 
Ruzzene, M., Pinna, L. A. (2010). Addiction to protein kinase CK2: a common 
denominator of diverse cancer cells? Biochimica et Biophysica Acta 1804(3): 499-504  
 
Salvi, M., Sarno, S., Cesaro, L., Nakamura, H. and Pinna, L. A. (2009). 
Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome 
analysis. Biochim. Biophys. Acta 1793(5): 847-859 
 
Sarno, S., Papinutto, E., Franchin, C., Bain, J., Elliott, M., Meggio, F., 
Kazimierczuk, Z., Orzeszko, A., Zanotti, G., Battistutta, R. and Pinna, L. A.(2001). ATP 
Site-Directed Inhibitors of Protein Kinase CK2: An Update. Current Topics in Medicinal 
Chemistry 11(11): 1340-51 
 
Scheer, M., Grote, A., Chang, A., Schomburg, I., Munaretto, C., Rother, M., 
Söhngen, C., Stelzer, M., Thiele, J., Schomburg, D. (2011). BRENDA, the enzyme 
information system in 2011. Nucleic Acids Res. 39: D670-676 
 
Sherr, C. J. and McCormick, F. (2002). The RB and p53 pathways in cancer. Cancer 
Cell 2: 103-112 
 
Shin, S., Lee, Y., Kim, W., Ko, H., Choi, H. and Kim, K. (2005). Caspase-2 primes 
cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J. 24: 
3532-3542 
 
St-Denis, N. A., Derksen, D. R. and Litchfield, D. W. (2009). Evidence for 
regulation of mitotic progression through temporal phosphorylation and 
dephosphorylation of CK2a. Mol. Cell. Biol. 29: 2068-2081 
 
St-Denis, N.A. and Litchfield, D. W. (2009). From birth to death: The role of 
protein kinase CK2 in the regulation of cell proliferation and survival. Cell. Mol. Life Sci. 
66: 1817-1829 
 
Tarrant, M. K., Rho, H. S., Xie, Z., Jiang, Y. L., Gross, C., Culhane, J. C., Yan, G., 
5. Bibliography 
119 
Qian, J., Ichikawa, Y., Matsuoka, T., Zachara, N., Etzkorn, F. A., Hart, G. W., Jeong, 
J. S., Blackshaw, S., Zhu, H., Cole, P. A. (2012). Regulation of CK2 by 
phosphorylation and O-GlcNAcylation revealed by semisynthesis. Nat Chem Biol. 
8: 262-269 
 
Taylor, S. S. and Kornev, A. P. (2011). Protein kinases: evolution of dynamic 
regulatory proteins. Trends Biochem. Sci. 36: 65-77 
 
Taylor, S. S., Keshwani, M. M., Steichen, J. M. and Kornev A. P. (2012). Evolution 
of the eukaryotic protein kinases as dynamic molecular switches. Phil. Trans. R. Soc. B 
367: 2517-2528 
 
Theis-Febvre, N., Martel, V., Laudet, B., Souchier, C., Grunwald, D., Cochet, C., 
Filhol, O. (2005). Highlighting protein kinase CK2 movement in living cells. Mol Cell 
Biochem 274: 15-22 
 
Tozser, J., Bagossi, P., Zahuczky, G., Specht, S. I., Majerova, E. and Copeland, T. 
D. (2003). Effect of caspase cleavage-site phosphorylation on proteolysis. Biochem. J. 
372: 137-143 
 
Valero, E., De Bonis, S., Filhol, O., Wade, R. H., Langowski, J., Chambaz, E. M., 
Cochet C. (1995). Quaternary structure of casein kinase 2. Characterization of multiple 
oligomeric states and relation with its catalytic activity. J Biol Chem. 270: 8345-8352 
 
Walsh, D. A., Perkins, J. P., Krebs E. G. (1968). An adenosine 3’,5’ -
monophosphate-dependant protein kinase from rabbit skeletal muscle. J. Biol. Chem. 243: 
3763-3765 
 
Xu, X., Toselli, P.A., Russell, L. D. and Seldin, D. C. (1999). Globozoospermia in 
mice lacking the casein kinase II alpha’ catalytic subunit. Nat. Genet. 23: 118-121 
 
 120 
  
 121 
Ringraziamenti 
 
Prima di tutto, ringrazio la mia happy family: mamma, papà, fede e cate… ricorderò 
per sempre il mio dottorato per tutto quello che ci è successo durante questi 3 anni! se 
penso a quante ne abbiamo passate! ma quello che è veramente importante è che sono qui 
a ricordare quei momenti con un sorriso e a godermi questi giorni tanto attesi. Abbiamo 
affrontato prove che nessuno meriterebbe di passare, ma sono tanto felice per noi, perché 
le abbiamo superate uniti. 
 
Un ringraziamento particolare alla mia sorellina Caterina. Sei stata, soprattutto nei 
momenti più cupi, fonte di sorriso e di forza quando rientravo da lavoro. Non lo 
dimenticherò mai. 
 
Ringrazio la mia Gre. Non ho parole per descrivere quanto tu sia stata importante 
per me durante questi 3 anni. Abbiamo affrontato tante avventure insieme, tantissimi 
ricordi, tante emozioni. Non avrei voluto avere vicino nessun altro. Grazie. 
 
Ringrazio particolarmente Roberto, per avermi accolto nel suo laboratorio per 
questi 3 anni e per le stimolanti discussioni scientifiche (e non) che mi hanno 
accompagnato durante il dottorato. 
 
Un ringraziamento particolare a Graziano, per tutto il “sapere” che hai cercato di 
trasmettermi…ne avessi appreso anche solo la metà, sarebbe già un gran risultato! 
Ricorderò sicuramente con piacere tutti i momenti che abbiamo passato insieme e le 
nostre chiacchierate…sempre in compagnia delle nostre amiche “bionde”. 
 
Ringrazio gli altri ragazzi del gruppo del Prof. Battistutta, Elisa, Denise, Michele 
per tutto il tempo che abbiamo condiviso. 
 
Ancora, mi trovo a ringraziare i miei amici Niec, Max, Panis, L.L.R., Alberto, Pier, 
Manu per aver avuto l’incredibile capacità di alleggerire qualsiasi momento pesante 
passato in questi 3 anni. 
Ringrazio i ragazzi del calcio amatori fossa lunga: vi siete presi la mia anima, ma 
 122 
senza di voi non avrei un fisico (e che fisico!!!). 
 
Ringrazio il Big Fede, ogni venerdì era come un film di Spike Lee. 
 
In generale, mi piace pensare che ricorderò tutte le persone con cui ho condiviso 
momenti più o meno simpatici duranti questi 3 anni. E’ mia volontà non dimenticarvi, 
perché il ricordo è l’unica via per l’immortalità! 
 
